[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fI9eSSX22vibh9ultrhenDTOcNtVpykUolU8Pl0vK_5M":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":86,"rows":93},"University of Cincinnati",[4],319,false,60,32,65362,25,170,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Stroke",18,{"name":18,"count":19},"Sarcoidosis",13,{"name":21,"count":22},"Bipolar Disorder",12,{"name":24,"count":25},"Traumatic Brain Injury",8,{"name":27,"count":28},"Depression",7,{"name":30,"count":31},"Anxiety",6,{"name":33,"count":34},"Lymphangioleiomyomatosis",5,{"name":36,"count":34},"Coronary Artery Disease",[38,43,48,53,58,63,67,72,77,81],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT04340258","Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC","2025-06-03","Pembrolizumab",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT04594772","Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma","2025-06-13","Folfirinox",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT03150914","Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial","2025-06-30","Sirolimus",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT04245436","Acute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A)","2025-07","Duloxetine",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT04245748","Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)","2025-07-30","Escitalopram",{"nctId":64,"briefTitle":65,"date":66,"intervention":52},"NCT02432560","Safety and Durability of Sirolimus for Treatment of LAM","2025-07-31",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT06679426","Safety and Efficacy of Conestat Alfa for ACE-Induced Angioedema","2025-12","Conestat Alfa",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT07231588","Oral 5 Strain Probiotic for GI Toxicity Mitigation During Pelvic Radiation","2026-06-29","Pendulum Glucose Control",{"nctId":78,"briefTitle":79,"date":80,"intervention":62},"NCT04623099","Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE)","2026-06-30",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT06574022","Post-mastectomy Recovery: Comparing Preoperative PECS-II Blocks With Intraoperative Pectoral Blocks","2026-08-01","Bupivacain",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,153,197,231,249,274,353,379,401,428,446,478,526,551,578,596,614,645,681,699,720,747,793,831,856,874,937,993,1041,1077,1120,1146,1179,1216,1238,1260,1296,1318,1357,1379,1404,1430,1448,1473,1497,1515,1543,1568,1593,1619,1643,1661,1679,1697,1715,1733,1751,1773,1796,1820,1843,1861,1879,1905,1923,1947,1965,1983,2006,2030,2055,2079,2106,2124,2149,2167,2192,2210,2228,2253,2271,2295,2319,2337,2363,2381,2399,2425,2449,2467,2492,2518,2536,2560,2578,2600,2623,2646,2664,2682,2707,2732,2750,2772,2794,2817,2835,2860,2878,2901,2923,2941,2964,2990,3008,3032,3055,3079,3097,3124,3148,3172,3197,3215,3240,3258,3283,3307,3325,3349,3372,3390,3414,3441,3459,3484,3502,3520,3543,3565,3583,3606,3629,3647,3665,3689,3707,3734,3752,3775,3796,3820,3842,3860,3888,3906,3924,3942,3960,3982,4007,4032,4050,4074,4092,4110,4128,4154,4202,4229,4258,4283,4310,4328,4346,4370,4394,4419,4447,4471,4489,4515,4538,4563,4581],{"intervention":62,"totalTrials":34,"cells":95},{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":101,"PHASE3":103,"PHASE4":105,"NA":131},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[],{"trials":102,"activeCount":98},[],{"trials":104,"activeCount":98},[],{"trials":106,"activeCount":130,"soonestReadout":56},[107,115,123],{"nctId":78,"briefTitle":79,"status":108,"phases":109,"primaryCompletion":80,"completion":110,"start":111,"enrollment":112,"conditions":113,"interventions":114},"RECRUITING",[91],"2026-12-01","2021-03-08",132,[30],[62],{"nctId":59,"briefTitle":60,"status":108,"phases":116,"primaryCompletion":61,"completion":117,"start":118,"enrollment":119,"conditions":120,"interventions":122},[91],"2025-12-31","2020-03-01",84,[121,27],"Anxious Depression",[62,57],{"nctId":54,"briefTitle":55,"status":108,"phases":124,"primaryCompletion":56,"completion":125,"start":126,"enrollment":8,"conditions":127,"interventions":129},[91],"2025-08","2020-01-01",[30,128],"Depressive Symptoms",[57,62],3,{"trials":132,"activeCount":98},[133,144],{"nctId":134,"briefTitle":135,"status":136,"phases":137,"primaryCompletion":138,"completion":139,"start":140,"enrollment":141,"conditions":142,"interventions":143},"NCT02553161","Mechanism of Antidepressant-Related Dysfunctional Arousal in High-Risk Youth","COMPLETED",[92],"2022-07","2022-12","2015-12",214,[27,30,21],[62],{"nctId":145,"briefTitle":146,"status":136,"phases":147,"primaryCompletion":148,"completion":149,"start":150,"enrollment":119,"conditions":151,"interventions":152},"NCT02818751","Neurofunctional Predictors of Escitalopram Treatment Response in Adolescents With Anxiety",[92],"2019-05","2020-05","2015-05",[30],[62],{"intervention":57,"totalTrials":154,"cells":155},4,{"EARLY_PHASE1":156,"PHASE1":158,"PHASE2":160,"PHASE3":162,"PHASE4":174,"NA":195},{"trials":157,"activeCount":98},[],{"trials":159,"activeCount":98},[],{"trials":161,"activeCount":98},[],{"trials":163,"activeCount":98},[164],{"nctId":165,"briefTitle":166,"status":136,"phases":167,"primaryCompletion":168,"completion":169,"start":170,"enrollment":8,"conditions":171,"interventions":173},"NCT00375973","Double Blind Trial of Duloxetine in Chronic Fatigue Syndrome",[89,90],"2012-06","2014-03","2006-09",[172],"Fatigue Syndrome, Chronic",[57],{"trials":175,"activeCount":194,"soonestReadout":56},[176,186,190],{"nctId":177,"briefTitle":178,"status":136,"phases":179,"primaryCompletion":180,"completion":180,"start":181,"enrollment":182,"conditions":183,"interventions":185},"NCT00607789","Study of Duloxetine vs Placebo in Treatment of Binge Eating Disorder With Depression",[91],"2009-10","2006-10",40,[184,27],"Binge Eating",[57],{"nctId":59,"briefTitle":60,"status":108,"phases":187,"primaryCompletion":61,"completion":117,"start":118,"enrollment":119,"conditions":188,"interventions":189},[91],[121,27],[62,57],{"nctId":54,"briefTitle":55,"status":108,"phases":191,"primaryCompletion":56,"completion":125,"start":126,"enrollment":8,"conditions":192,"interventions":193},[91],[30,128],[57,62],2,{"trials":196,"activeCount":98},[],{"intervention":198,"totalTrials":194,"cells":199},"Exparel",{"EARLY_PHASE1":200,"PHASE1":202,"PHASE2":204,"PHASE3":206,"PHASE4":208,"NA":229},{"trials":201,"activeCount":98},[],{"trials":203,"activeCount":98},[],{"trials":205,"activeCount":98},[],{"trials":207,"activeCount":98},[],{"trials":209,"activeCount":228,"soonestReadout":84},[210,218],{"nctId":82,"briefTitle":83,"status":108,"phases":211,"primaryCompletion":84,"completion":110,"start":212,"enrollment":213,"conditions":214,"interventions":217},[91],"2024-09-25",100,[215,216],"Mastectomy; Lymphedema","Breast Cancer",[85,198],{"nctId":219,"briefTitle":220,"status":136,"phases":221,"primaryCompletion":222,"completion":222,"start":223,"enrollment":224,"conditions":225,"interventions":227},"NCT03929146","Liposomal Bupivacaine Versus Interscalene Nerve Block",[91],"2022-11-01","2019-02-05",76,[226],"Pain, Postoperative",[198],1,{"trials":230,"activeCount":98},[],{"intervention":85,"totalTrials":228,"cells":232},{"EARLY_PHASE1":233,"PHASE1":235,"PHASE2":237,"PHASE3":239,"PHASE4":241,"NA":247},{"trials":234,"activeCount":98},[],{"trials":236,"activeCount":98},[],{"trials":238,"activeCount":98},[],{"trials":240,"activeCount":98},[],{"trials":242,"activeCount":228,"soonestReadout":84},[243],{"nctId":82,"briefTitle":83,"status":108,"phases":244,"primaryCompletion":84,"completion":110,"start":212,"enrollment":213,"conditions":245,"interventions":246},[91],[215,216],[85,198],{"trials":248,"activeCount":98},[],{"intervention":250,"totalTrials":228,"cells":251},"sertraline",{"EARLY_PHASE1":252,"PHASE1":254,"PHASE2":256,"PHASE3":258,"PHASE4":260,"NA":272},{"trials":253,"activeCount":98},[],{"trials":255,"activeCount":98},[],{"trials":257,"activeCount":98},[],{"trials":259,"activeCount":98},[],{"trials":261,"activeCount":228,"soonestReadout":266},[262],{"nctId":263,"briefTitle":264,"status":108,"phases":265,"primaryCompletion":266,"completion":266,"start":267,"enrollment":268,"conditions":269,"interventions":271},"NCT04221997","Trial With the Treatment of Sertraline in Youth With Generalized, Separation and\u002For Social Anxiety Disorders.",[91],"2026-09","2019-11-01",150,[270],"Anxiety Disorders",[250],{"trials":273,"activeCount":98},[],{"intervention":52,"totalTrials":28,"cells":275},{"EARLY_PHASE1":276,"PHASE1":278,"PHASE2":280,"PHASE3":301,"PHASE4":320,"NA":344},{"trials":277,"activeCount":98},[],{"trials":279,"activeCount":98},[],{"trials":281,"activeCount":98},[282,291],{"nctId":283,"briefTitle":284,"status":136,"phases":285,"primaryCompletion":286,"completion":286,"start":287,"enrollment":11,"conditions":288,"interventions":289},"NCT03253913","Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial",[89],"2022-10-15","2018-03-31",[33],[52,290],"Resveratrol",{"nctId":292,"briefTitle":293,"status":136,"phases":294,"primaryCompletion":295,"completion":296,"start":297,"enrollment":9,"conditions":298,"interventions":300},"NCT04341675","Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia",[89],"2020-07-15","2020-09-15","2020-04-24",[299],"COVID-19",[52],{"trials":302,"activeCount":228,"soonestReadout":51},[303,310],{"nctId":49,"briefTitle":50,"status":304,"phases":305,"primaryCompletion":51,"completion":51,"start":306,"enrollment":8,"conditions":307,"interventions":309},"ACTIVE_NOT_RECRUITING",[90],"2018-01-01",[308,33],"LAM",[52],{"nctId":311,"briefTitle":312,"status":136,"phases":313,"primaryCompletion":314,"completion":315,"start":316,"enrollment":317,"conditions":318,"interventions":319},"NCT00414648","Efficacy and Safety of Sirolimus in LAM",[90],"2010-09","2011-02","2006-12",89,[33],[52],{"trials":321,"activeCount":98},[322,335],{"nctId":323,"briefTitle":324,"status":136,"phases":325,"primaryCompletion":326,"completion":326,"start":327,"enrollment":328,"conditions":329,"interventions":331},"NCT00352092","Pilot Study for HLA Identical Living Donor Renal Transplant Recipients",[91],"2007-12","2002-06",20,[330],"Renal Transplant",[332,333,334],"calcineurin inhibitor","sirolimus","mycophenolate mofetil",{"nctId":336,"briefTitle":337,"status":136,"phases":338,"primaryCompletion":326,"completion":326,"start":339,"enrollment":340,"conditions":341,"interventions":343},"NCT00374647","Study to Evaluate Safety and Efficacy of Early Calcineurin Inhibitor Withdrawal in Primary Renal Allografts",[91],"2005-03",17,[342],"Primary Renal Allograft",[334,333],{"trials":345,"activeCount":228,"soonestReadout":66},[346],{"nctId":64,"briefTitle":65,"status":108,"phases":347,"primaryCompletion":66,"completion":66,"start":348,"enrollment":349,"conditions":350,"interventions":351},[],"2015-03",600,[33],[52,352],"Everolimus",{"intervention":354,"totalTrials":228,"cells":355},"N-acetylcysteine",{"EARLY_PHASE1":356,"PHASE1":358,"PHASE2":360,"PHASE3":362,"PHASE4":375,"NA":377},{"trials":357,"activeCount":98},[],{"trials":359,"activeCount":98},[],{"trials":361,"activeCount":98},[],{"trials":363,"activeCount":228,"soonestReadout":368},[364],{"nctId":365,"briefTitle":366,"status":108,"phases":367,"primaryCompletion":368,"completion":369,"start":370,"enrollment":371,"conditions":372,"interventions":374},"NCT07464886","Prefrontal Glutamatergic Modulation by NAC and MBCT for Depression in Youth",[90],"2030-03","2030-12","2026-02-26",160,[373],"Mild Depression",[354],{"trials":376,"activeCount":98},[],{"trials":378,"activeCount":98},[],{"intervention":71,"totalTrials":228,"cells":380},{"EARLY_PHASE1":381,"PHASE1":383,"PHASE2":385,"PHASE3":387,"PHASE4":397,"NA":399},{"trials":382,"activeCount":98},[],{"trials":384,"activeCount":98},[],{"trials":386,"activeCount":98},[],{"trials":388,"activeCount":228,"soonestReadout":70},[389],{"nctId":68,"briefTitle":69,"status":390,"phases":391,"primaryCompletion":70,"completion":70,"start":392,"enrollment":393,"conditions":394,"interventions":396},"NOT_YET_RECRUITING",[90],"2024-12-01",24,[395],"ACE Inhibitor-Induced Angioedema",[71],{"trials":398,"activeCount":98},[],{"trials":400,"activeCount":98},[],{"intervention":402,"totalTrials":228,"cells":403},"Capecitabine",{"EARLY_PHASE1":404,"PHASE1":406,"PHASE2":408,"PHASE3":410,"PHASE4":424,"NA":426},{"trials":405,"activeCount":98},[],{"trials":407,"activeCount":98},[],{"trials":409,"activeCount":98},[],{"trials":411,"activeCount":228,"soonestReadout":416},[412],{"nctId":413,"briefTitle":414,"status":304,"phases":415,"primaryCompletion":416,"completion":417,"start":418,"enrollment":419,"conditions":420,"interventions":422},"NCT05902533","REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation",[89,90],"2026-08-14","2029-08-14","2023-08-14",33,[421],"Anal Cancer",[402,423],"Mitomycin c",{"trials":425,"activeCount":98},[],{"trials":427,"activeCount":98},[],{"intervention":423,"totalTrials":228,"cells":429},{"EARLY_PHASE1":430,"PHASE1":432,"PHASE2":434,"PHASE3":436,"PHASE4":442,"NA":444},{"trials":431,"activeCount":98},[],{"trials":433,"activeCount":98},[],{"trials":435,"activeCount":98},[],{"trials":437,"activeCount":228,"soonestReadout":416},[438],{"nctId":413,"briefTitle":414,"status":304,"phases":439,"primaryCompletion":416,"completion":417,"start":418,"enrollment":419,"conditions":440,"interventions":441},[89,90],[421],[402,423],{"trials":443,"activeCount":98},[],{"trials":445,"activeCount":98},[],{"intervention":42,"totalTrials":194,"cells":447},{"EARLY_PHASE1":448,"PHASE1":450,"PHASE2":452,"PHASE3":472,"PHASE4":474,"NA":476},{"trials":449,"activeCount":98},[],{"trials":451,"activeCount":98},[],{"trials":453,"activeCount":194,"soonestReadout":41},[454,464],{"nctId":455,"briefTitle":456,"status":108,"phases":457,"primaryCompletion":369,"completion":458,"start":459,"enrollment":182,"conditions":460,"interventions":463},"NCT07213934","Phase I\u002F II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma",[88,89],"2031-12","2025-10-08",[461,462],"Head and Neck Cancer","Recurrent Head and Neck Squamous Cell Carcinoma",[42],{"nctId":39,"briefTitle":40,"status":304,"phases":465,"primaryCompletion":41,"completion":466,"start":467,"enrollment":468,"conditions":469,"interventions":471},[88,89],"2025-09-04","2021-02-04",50,[470],"HNSCC",[42],{"trials":473,"activeCount":98},[],{"trials":475,"activeCount":98},[],{"trials":477,"activeCount":98},[],{"intervention":479,"totalTrials":130,"cells":480},"Gemcitabine",{"EARLY_PHASE1":481,"PHASE1":483,"PHASE2":498,"PHASE3":520,"PHASE4":522,"NA":524},{"trials":482,"activeCount":98},[],{"trials":484,"activeCount":98},[485],{"nctId":486,"briefTitle":487,"status":136,"phases":488,"primaryCompletion":489,"completion":490,"start":491,"enrollment":393,"conditions":492,"interventions":495},"NCT02071537","Chloroquine in Combination With Carboplatin\u002FGemcitabine in Advanced Solid Tumors",[88],"2018-03-03","2018-12","2014-05-13",[493,494],"Malignant Neoplasm","Solid Tumors",[496,497,479],"Chloroquine","Carboplatin",{"trials":499,"activeCount":228,"soonestReadout":46},[500,513],{"nctId":501,"briefTitle":502,"status":503,"phases":504,"primaryCompletion":505,"completion":506,"start":507,"enrollment":98,"conditions":508,"interventions":510},"NCT00728000","Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma","WITHDRAWN",[89],"2009-08","2010-08","2008-08",[509],"Pancreatic Adenocarcinoma",[479,511,512],"Oxaliplatin","Erlotinib",{"nctId":44,"briefTitle":45,"status":304,"phases":514,"primaryCompletion":46,"completion":515,"start":516,"enrollment":9,"conditions":517,"interventions":519},[89],"2026-06-01","2021-03-17",[518],"Pancreas Cancer",[47,479],{"trials":521,"activeCount":98},[],{"trials":523,"activeCount":98},[],{"trials":525,"activeCount":98},[],{"intervention":527,"totalTrials":228,"cells":528},"Treatment Algorithm",{"EARLY_PHASE1":529,"PHASE1":531,"PHASE2":533,"PHASE3":545,"PHASE4":547,"NA":549},{"trials":530,"activeCount":98},[],{"trials":532,"activeCount":98},[],{"trials":534,"activeCount":228,"soonestReadout":539},[535],{"nctId":536,"briefTitle":537,"status":108,"phases":538,"primaryCompletion":539,"completion":540,"start":541,"enrollment":542,"conditions":543,"interventions":544},"NCT05337618","Improving Neurotrauma by Depolarization Inhibition With Combination Therapy (INDICT)",[89],"2026-09-01","2027-03-20","2022-12-16",72,[24],[527],{"trials":546,"activeCount":98},[],{"trials":548,"activeCount":98},[],{"trials":550,"activeCount":98},[],{"intervention":552,"totalTrials":228,"cells":553},"AM3101",{"EARLY_PHASE1":554,"PHASE1":556,"PHASE2":558,"PHASE3":572,"PHASE4":574,"NA":576},{"trials":555,"activeCount":98},[],{"trials":557,"activeCount":98},[],{"trials":559,"activeCount":228,"soonestReadout":564},[560],{"nctId":561,"briefTitle":562,"status":108,"phases":563,"primaryCompletion":564,"completion":565,"start":566,"enrollment":567,"conditions":568,"interventions":570},"NCT05560477","Study to Evaluate the Safety and Efficacy of AM3101 to Augment Meniscal Healing",[88,89],"2027-01","2027-06","2023-04-26",74,[569],"Meniscus Tear",[552,571],"Saline Placebo",{"trials":573,"activeCount":98},[],{"trials":575,"activeCount":98},[],{"trials":577,"activeCount":98},[],{"intervention":571,"totalTrials":228,"cells":579},{"EARLY_PHASE1":580,"PHASE1":582,"PHASE2":584,"PHASE3":590,"PHASE4":592,"NA":594},{"trials":581,"activeCount":98},[],{"trials":583,"activeCount":98},[],{"trials":585,"activeCount":228,"soonestReadout":564},[586],{"nctId":561,"briefTitle":562,"status":108,"phases":587,"primaryCompletion":564,"completion":565,"start":566,"enrollment":567,"conditions":588,"interventions":589},[88,89],[569],[552,571],{"trials":591,"activeCount":98},[],{"trials":593,"activeCount":98},[],{"trials":595,"activeCount":98},[],{"intervention":47,"totalTrials":228,"cells":597},{"EARLY_PHASE1":598,"PHASE1":600,"PHASE2":602,"PHASE3":608,"PHASE4":610,"NA":612},{"trials":599,"activeCount":98},[],{"trials":601,"activeCount":98},[],{"trials":603,"activeCount":228,"soonestReadout":46},[604],{"nctId":44,"briefTitle":45,"status":304,"phases":605,"primaryCompletion":46,"completion":515,"start":516,"enrollment":9,"conditions":606,"interventions":607},[89],[518],[47,479],{"trials":609,"activeCount":98},[],{"trials":611,"activeCount":98},[],{"trials":613,"activeCount":98},[],{"intervention":615,"totalTrials":228,"cells":616},"Minocycline",{"EARLY_PHASE1":617,"PHASE1":619,"PHASE2":637,"PHASE3":639,"PHASE4":641,"NA":643},{"trials":618,"activeCount":98},[],{"trials":620,"activeCount":228,"soonestReadout":625},[621],{"nctId":622,"briefTitle":623,"status":390,"phases":624,"primaryCompletion":625,"completion":626,"start":110,"enrollment":627,"conditions":628,"interventions":636},"NCT05605366","Minocycline In Neurocognitive Outcomes - Sickle Cell Disease",[88],"2027-12-31","2028-06-15",30,[629,630,631,632,633,634,635],"Sickle Cell Disease","Cognitive Impairment","Cognitive Decline","Cognitive Change","Cognitive Dysfunction","Cognitive Deficit","Neuroinflammatory Response",[615],{"trials":638,"activeCount":98},[],{"trials":640,"activeCount":98},[],{"trials":642,"activeCount":98},[],{"trials":644,"activeCount":98},[],{"intervention":646,"totalTrials":194,"cells":647},"Letrozole Oral",{"EARLY_PHASE1":648,"PHASE1":662,"PHASE2":664,"PHASE3":675,"PHASE4":677,"NA":679},{"trials":649,"activeCount":228,"soonestReadout":654},[650],{"nctId":651,"briefTitle":652,"status":108,"phases":653,"primaryCompletion":654,"completion":655,"start":656,"enrollment":657,"conditions":658,"interventions":660},"NCT03122197","Study of Letrozole in Recurrent Gliomas",[87],"2027-09-01","2027-12","2017-05-16",39,[659],"Brain Tumor",[646,661],"Temozolomide",{"trials":663,"activeCount":98},[],{"trials":665,"activeCount":98},[666],{"nctId":667,"briefTitle":668,"status":136,"phases":669,"primaryCompletion":670,"completion":670,"start":671,"enrollment":340,"conditions":672,"interventions":673},"NCT01353209","Letrozole for Lymphangioleiomyomatosis",[89],"2014-09","2011-05",[33],[674],"Letrozole",{"trials":676,"activeCount":98},[],{"trials":678,"activeCount":98},[],{"trials":680,"activeCount":98},[],{"intervention":661,"totalTrials":228,"cells":682},{"EARLY_PHASE1":683,"PHASE1":689,"PHASE2":691,"PHASE3":693,"PHASE4":695,"NA":697},{"trials":684,"activeCount":228,"soonestReadout":654},[685],{"nctId":651,"briefTitle":652,"status":108,"phases":686,"primaryCompletion":654,"completion":655,"start":656,"enrollment":657,"conditions":687,"interventions":688},[87],[659],[646,661],{"trials":690,"activeCount":98},[],{"trials":692,"activeCount":98},[],{"trials":694,"activeCount":98},[],{"trials":696,"activeCount":98},[],{"trials":698,"activeCount":98},[],{"intervention":76,"totalTrials":228,"cells":700},{"EARLY_PHASE1":701,"PHASE1":710,"PHASE2":712,"PHASE3":714,"PHASE4":716,"NA":718},{"trials":702,"activeCount":228,"soonestReadout":75},[703],{"nctId":73,"briefTitle":74,"status":108,"phases":704,"primaryCompletion":75,"completion":705,"start":706,"enrollment":328,"conditions":707,"interventions":709},[87],"2026-12-29","2026-01-29",[708],"Radiation Injuries",[76],{"trials":711,"activeCount":98},[],{"trials":713,"activeCount":98},[],{"trials":715,"activeCount":98},[],{"trials":717,"activeCount":98},[],{"trials":719,"activeCount":98},[],{"intervention":721,"totalTrials":228,"cells":722},"C-peptide",{"EARLY_PHASE1":723,"PHASE1":737,"PHASE2":739,"PHASE3":741,"PHASE4":743,"NA":745},{"trials":724,"activeCount":228,"soonestReadout":729},[725],{"nctId":726,"briefTitle":727,"status":108,"phases":728,"primaryCompletion":729,"completion":730,"start":731,"enrollment":732,"conditions":733,"interventions":736},"NCT06470295","Effect of C-peptide on Hypoglycemic Counterregulation",[87],"2027-06-01","2028-01-01","2024-06-01",38,[734,735],"Hypoglycemia","Type 1 Diabetes",[721],{"trials":738,"activeCount":98},[],{"trials":740,"activeCount":98},[],{"trials":742,"activeCount":98},[],{"trials":744,"activeCount":98},[],{"trials":746,"activeCount":98},[],{"intervention":352,"totalTrials":130,"cells":748},{"EARLY_PHASE1":749,"PHASE1":751,"PHASE2":766,"PHASE3":768,"PHASE4":770,"NA":787},{"trials":750,"activeCount":98},[],{"trials":752,"activeCount":98},[753],{"nctId":754,"briefTitle":755,"status":756,"phases":757,"primaryCompletion":758,"completion":759,"start":760,"enrollment":761,"conditions":762,"interventions":764},"NCT01508104","Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors","TERMINATED",[88],"2014-02","2014-12","2012-01",19,[763],"Cancer",[765,352],"BEZ235",{"trials":767,"activeCount":98},[],{"trials":769,"activeCount":98},[],{"trials":771,"activeCount":98},[772],{"nctId":773,"briefTitle":774,"status":775,"phases":776,"primaryCompletion":777,"completion":778,"start":779,"enrollment":780,"conditions":781,"interventions":783},"NCT04849533","Belatacept With Early Steroid Withdrawal rATG and Everolimus in Renal Transplantation (BETTER Trial)","UNKNOWN",[91],"2023-07","2024-07","2021-04-09",120,[782],"Kidney Transplant Rejection",[784,352,334,785,786],"Belatacept","corticosteroids","rabbit antithymocyte globulin",{"trials":788,"activeCount":228,"soonestReadout":66},[789],{"nctId":64,"briefTitle":65,"status":108,"phases":790,"primaryCompletion":66,"completion":66,"start":348,"enrollment":349,"conditions":791,"interventions":792},[],[33],[52,352],{"intervention":794,"totalTrials":194,"cells":795},"Bevacizumab",{"EARLY_PHASE1":796,"PHASE1":798,"PHASE2":800,"PHASE3":813,"PHASE4":815,"NA":817},{"trials":797,"activeCount":98},[],{"trials":799,"activeCount":98},[],{"trials":801,"activeCount":98},[802],{"nctId":803,"briefTitle":804,"status":503,"phases":805,"primaryCompletion":806,"completion":806,"start":807,"enrollment":98,"conditions":808,"interventions":810},"NCT00984438","Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme",[88,89],"2010-06","2009-06",[809],"Glioblastoma Multiforme",[811,812,794],"BCNU Wafer","Irinotecan",{"trials":814,"activeCount":98},[],{"trials":816,"activeCount":98},[],{"trials":818,"activeCount":228,"soonestReadout":823},[819],{"nctId":820,"briefTitle":821,"status":390,"phases":822,"primaryCompletion":823,"completion":824,"start":825,"enrollment":826,"conditions":827,"interventions":829},"NCT07274787","Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma",[92],"2028-06-01","2029-06-01","2026-01-01",10,[828],"GBM",[830,794],"Lumason",{"intervention":832,"totalTrials":228,"cells":833},"chemotherapy",{"EARLY_PHASE1":834,"PHASE1":836,"PHASE2":838,"PHASE3":840,"PHASE4":842,"NA":844},{"trials":835,"activeCount":98},[],{"trials":837,"activeCount":98},[],{"trials":839,"activeCount":98},[],{"trials":841,"activeCount":98},[],{"trials":843,"activeCount":98},[],{"trials":845,"activeCount":228,"soonestReadout":850},[846],{"nctId":847,"briefTitle":848,"status":304,"phases":849,"primaryCompletion":850,"completion":850,"start":851,"enrollment":852,"conditions":853,"interventions":855},"NCT00938145","3 Tesla MRI in Patients With Bladder Cancer",[92],"2026-12-31","2009-07-08",98,[854],"Bladder Cancer",[832],{"intervention":830,"totalTrials":228,"cells":857},{"EARLY_PHASE1":858,"PHASE1":860,"PHASE2":862,"PHASE3":864,"PHASE4":866,"NA":868},{"trials":859,"activeCount":98},[],{"trials":861,"activeCount":98},[],{"trials":863,"activeCount":98},[],{"trials":865,"activeCount":98},[],{"trials":867,"activeCount":98},[],{"trials":869,"activeCount":228,"soonestReadout":823},[870],{"nctId":820,"briefTitle":821,"status":390,"phases":871,"primaryCompletion":823,"completion":824,"start":825,"enrollment":826,"conditions":872,"interventions":873},[92],[828],[830,794],{"intervention":334,"totalTrials":31,"cells":875},{"EARLY_PHASE1":876,"PHASE1":878,"PHASE2":880,"PHASE3":882,"PHASE4":884,"NA":935},{"trials":877,"activeCount":98},[],{"trials":879,"activeCount":98},[],{"trials":881,"activeCount":98},[],{"trials":883,"activeCount":98},[],{"trials":885,"activeCount":98},[886,890,903,907,920,924],{"nctId":323,"briefTitle":324,"status":136,"phases":887,"primaryCompletion":326,"completion":326,"start":327,"enrollment":328,"conditions":888,"interventions":889},[91],[330],[332,333,334],{"nctId":891,"briefTitle":892,"status":136,"phases":893,"primaryCompletion":894,"completion":894,"start":895,"enrollment":896,"conditions":897,"interventions":899},"NCT02221583","Pharmacokinetics of Immunosuppressants in Renal Transplant Candidates Who Have Undergone Laparoscopic Sleeve Gastrectomy",[91],"2015-02","2014-05",26,[898],"End Stage Renal Disease",[900,901,902],"Astagraf XL","Prograf","Mycophenolate mofetil",{"nctId":336,"briefTitle":337,"status":136,"phases":904,"primaryCompletion":326,"completion":326,"start":339,"enrollment":340,"conditions":905,"interventions":906},[91],[342],[334,333],{"nctId":908,"briefTitle":909,"status":136,"phases":910,"primaryCompletion":490,"completion":911,"start":912,"enrollment":913,"conditions":914,"interventions":916},"NCT01729494","Belatacept Early Steroid Withdrawal Trial",[91],"2019-12","2012-09",316,[915],"Renal Transplantation",[917,786,784,918,902,919],"Alemtuzumab","Tacrolimus","early cessation of steroids",{"nctId":773,"briefTitle":774,"status":775,"phases":921,"primaryCompletion":777,"completion":778,"start":779,"enrollment":780,"conditions":922,"interventions":923},[91],[782],[784,352,334,785,786],{"nctId":925,"briefTitle":926,"status":136,"phases":927,"primaryCompletion":928,"completion":928,"start":929,"enrollment":182,"conditions":930,"interventions":932},"NCT00374231","Single Center Pilot Study of Corticosteroid Discontinuation in Liver Transplant Recipients",[91],"2008-01","2002-10",[931],"Liver Transplantation",[933,334,934],"tacrolimus","Prednisone",{"trials":936,"activeCount":98},[],{"intervention":938,"totalTrials":154,"cells":939},"Methylphenidate",{"EARLY_PHASE1":940,"PHASE1":942,"PHASE2":944,"PHASE3":957,"PHASE4":980,"NA":991},{"trials":941,"activeCount":98},[],{"trials":943,"activeCount":98},[],{"trials":945,"activeCount":98},[946],{"nctId":947,"briefTitle":948,"status":136,"phases":949,"completion":950,"start":951,"enrollment":627,"conditions":952,"interventions":954},"NCT00414921","Preschool Supplement to Clonidine in ADHD (Kiddie-CAT)",[89],"2007-06","2003-09",[953],"Attention Deficit Hyperactivity Disorder",[955,956],"clonidine","methylphenidate",{"trials":958,"activeCount":98},[959,971],{"nctId":960,"briefTitle":961,"status":136,"phases":962,"primaryCompletion":963,"completion":963,"start":964,"enrollment":965,"conditions":966,"interventions":969},"NCT00264797","Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents With Substance Use Disorders (SUD)",[90],"2008-10","2006-02",303,[967,968],"ADHD","Substance Abuse",[938,970],"Methylphenidate (OROS-MPH) - Placebo",{"nctId":972,"briefTitle":973,"status":136,"phases":974,"completion":950,"start":975,"enrollment":976,"conditions":977,"interventions":979},"NCT00031395","Clonidine in Attention Deficit Hyperactivity Disorder (ADHD) in Children",[90],"1999-09",122,[978],"Attention Deficit Disorder With Hyperactivity",[955,956],{"trials":981,"activeCount":98},[982],{"nctId":983,"briefTitle":984,"status":136,"phases":985,"primaryCompletion":180,"completion":180,"start":326,"enrollment":986,"conditions":987,"interventions":990},"NCT00526630","Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease",[91],23,[988,989],"Parkinson's Disease","Gait Impairment",[938],{"trials":992,"activeCount":98},[],{"intervention":994,"totalTrials":154,"cells":995},"Rabbit Antithymocyte Globulin",{"EARLY_PHASE1":996,"PHASE1":998,"PHASE2":1000,"PHASE3":1017,"PHASE4":1019,"NA":1039},{"trials":997,"activeCount":98},[],{"trials":999,"activeCount":98},[],{"trials":1001,"activeCount":98},[1002],{"nctId":1003,"briefTitle":1004,"status":136,"phases":1005,"primaryCompletion":1006,"completion":1007,"start":1008,"enrollment":627,"conditions":1009,"interventions":1011},"NCT00771875","Randomized Trial for Mixed Acute Rejection",[89],"2012-12","2013-03","2008-09",[1010],"Graft Rejection",[994,1012,1013,1014,1015,1016],"Rituximab","Bortezomib","Acetaminophen","Antihistamine","Methylprednisolone",{"trials":1018,"activeCount":98},[],{"trials":1020,"activeCount":98},[1021,1031,1035],{"nctId":1022,"briefTitle":1023,"status":136,"phases":1024,"primaryCompletion":1025,"completion":1007,"start":1008,"enrollment":182,"conditions":1026,"interventions":1028},"NCT00782821","Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients",[91],"2013-02",[1027],"Kidney Transplantation",[994,1029,1030],"Velcade","Rituxan",{"nctId":908,"briefTitle":909,"status":136,"phases":1032,"primaryCompletion":490,"completion":911,"start":912,"enrollment":913,"conditions":1033,"interventions":1034},[91],[915],[917,786,784,918,902,919],{"nctId":773,"briefTitle":774,"status":775,"phases":1036,"primaryCompletion":777,"completion":778,"start":779,"enrollment":780,"conditions":1037,"interventions":1038},[91],[782],[784,352,334,785,786],{"trials":1040,"activeCount":98},[],{"intervention":1012,"totalTrials":130,"cells":1042},{"EARLY_PHASE1":1043,"PHASE1":1045,"PHASE2":1047,"PHASE3":1060,"PHASE4":1062,"NA":1075},{"trials":1044,"activeCount":98},[],{"trials":1046,"activeCount":98},[],{"trials":1048,"activeCount":98},[1049,1056],{"nctId":1050,"briefTitle":1051,"status":136,"phases":1052,"primaryCompletion":1006,"completion":1006,"start":1053,"enrollment":826,"conditions":1054,"interventions":1055},"NCT00855205","Rituximab for Pulmonary Sarcoidosis",[89],"2009-07",[18],[1012],{"nctId":1003,"briefTitle":1004,"status":136,"phases":1057,"primaryCompletion":1006,"completion":1007,"start":1008,"enrollment":627,"conditions":1058,"interventions":1059},[89],[1010],[994,1012,1013,1014,1015,1016],{"trials":1061,"activeCount":98},[],{"trials":1063,"activeCount":98},[1064],{"nctId":1065,"briefTitle":1066,"status":136,"phases":1067,"primaryCompletion":1068,"completion":1068,"start":1069,"enrollment":1070,"conditions":1071,"interventions":1073},"NCT00908583","Desensitization in Kidney Transplantation",[91],"2012-11","2009-05",44,[1072],"HLA Sensitization",[1074,1013,1012,1016],"plasmapheresis",{"trials":1076,"activeCount":98},[],{"intervention":901,"totalTrials":130,"cells":1078},{"EARLY_PHASE1":1079,"PHASE1":1081,"PHASE2":1083,"PHASE3":1085,"PHASE4":1087,"NA":1118},{"trials":1080,"activeCount":98},[],{"trials":1082,"activeCount":98},[],{"trials":1084,"activeCount":98},[],{"trials":1086,"activeCount":98},[],{"trials":1088,"activeCount":98},[1089,1103,1107],{"nctId":1090,"briefTitle":1091,"status":136,"phases":1092,"primaryCompletion":1093,"completion":1093,"start":348,"enrollment":1094,"conditions":1095,"interventions":1097},"NCT02014103","Conversion From Brand to Generic Tacrolimus in High Risk Transplant Recipients",[91],"2015-08",71,[1096],"Complication of Transplant",[901,1098,1099,1100,1101,1102],"Tacrolimus, Sandoz","Tacrolimus, Reddy Laboratory","Tacrolimus, Mylan","Tacrolimus, Accord","Tacrolimus, Pancea Biotech Limited",{"nctId":891,"briefTitle":892,"status":136,"phases":1104,"primaryCompletion":894,"completion":894,"start":895,"enrollment":896,"conditions":1105,"interventions":1106},[91],[898],[900,901,902],{"nctId":1108,"briefTitle":1109,"status":136,"phases":1110,"primaryCompletion":1111,"completion":1111,"start":1112,"enrollment":1113,"conditions":1114,"interventions":1117},"NCT01889758","Pharmacokinetic Studies of Tacrolimus in Transplant Patients",[91],"2016-01","2013-06",78,[1115,1116],"Kidney Transplant Recipients","Liver Transplant Recipients",[901,918,918],{"trials":1119,"activeCount":98},[],{"intervention":918,"totalTrials":130,"cells":1121},{"EARLY_PHASE1":1122,"PHASE1":1124,"PHASE2":1126,"PHASE3":1128,"PHASE4":1130,"NA":1144},{"trials":1123,"activeCount":98},[],{"trials":1125,"activeCount":98},[],{"trials":1127,"activeCount":98},[],{"trials":1129,"activeCount":98},[],{"trials":1131,"activeCount":98},[1132,1136,1140],{"nctId":1108,"briefTitle":1109,"status":136,"phases":1133,"primaryCompletion":1111,"completion":1111,"start":1112,"enrollment":1113,"conditions":1134,"interventions":1135},[91],[1115,1116],[901,918,918],{"nctId":908,"briefTitle":909,"status":136,"phases":1137,"primaryCompletion":490,"completion":911,"start":912,"enrollment":913,"conditions":1138,"interventions":1139},[91],[915],[917,786,784,918,902,919],{"nctId":925,"briefTitle":926,"status":136,"phases":1141,"primaryCompletion":928,"completion":928,"start":929,"enrollment":182,"conditions":1142,"interventions":1143},[91],[931],[933,334,934],{"trials":1145,"activeCount":98},[],{"intervention":1147,"totalTrials":194,"cells":1148},"Mycophenolic Acid",{"EARLY_PHASE1":1149,"PHASE1":1151,"PHASE2":1153,"PHASE3":1155,"PHASE4":1157,"NA":1177},{"trials":1150,"activeCount":98},[],{"trials":1152,"activeCount":98},[],{"trials":1154,"activeCount":98},[],{"trials":1156,"activeCount":98},[],{"trials":1158,"activeCount":98},[1159,1168],{"nctId":1160,"briefTitle":1161,"status":136,"phases":1162,"primaryCompletion":928,"completion":928,"start":1163,"enrollment":1164,"conditions":1165,"interventions":1167},"NCT00374803","Study of Myfortic in Combination With Tacrolimus and Thymoglobulin in Early Corticosteroid Withdrawal",[91],"2006-04",45,[1166],"End Stage Renal Disease (ESRD)",[1147],{"nctId":1169,"briefTitle":1170,"status":136,"phases":1171,"primaryCompletion":1172,"completion":1172,"start":314,"enrollment":1173,"conditions":1174,"interventions":1175},"NCT01336296","Evaluate Effects and Safety of Pre-load Myfortic® in Transplant Patients",[91],"2014-04",61,[1115],[1176],"mycophenolic acid",{"trials":1178,"activeCount":98},[],{"intervention":1180,"totalTrials":194,"cells":1181},"Intranasal Ketamine",{"EARLY_PHASE1":1182,"PHASE1":1184,"PHASE2":1186,"PHASE3":1188,"PHASE4":1202,"NA":1214},{"trials":1183,"activeCount":98},[],{"trials":1185,"activeCount":98},[],{"trials":1187,"activeCount":98},[],{"trials":1189,"activeCount":98},[1190],{"nctId":1191,"briefTitle":1192,"status":775,"phases":1193,"primaryCompletion":1194,"completion":1195,"start":1196,"enrollment":8,"conditions":1197,"interventions":1200},"NCT02183272","Emergency Ketamine Treatment of Suicidal Ideation",[89,90],"2017-11","2018-07","2016-08",[27,1198,1199],"Suicidal Ideation","Suicidal Impulses",[1180,1201],"Intranasal Saline Placebo",{"trials":1203,"activeCount":98},[1204],{"nctId":1205,"briefTitle":1206,"status":775,"phases":1207,"primaryCompletion":1208,"completion":1208,"start":1209,"enrollment":328,"conditions":1210,"interventions":1212},"NCT04352621","Study to Assess the Effects of Intranasal Ketamine Along With rTMS for Patients With Treatment-resistant Major Depressive Disorder (TRD)",[91],"2022-05-01","2020-05-01",[1211],"Major Depressive Disorder",[1213],"intranasal ketamine",{"trials":1215,"activeCount":98},[],{"intervention":1013,"totalTrials":194,"cells":1217},{"EARLY_PHASE1":1218,"PHASE1":1220,"PHASE2":1222,"PHASE3":1228,"PHASE4":1230,"NA":1236},{"trials":1219,"activeCount":98},[],{"trials":1221,"activeCount":98},[],{"trials":1223,"activeCount":98},[1224],{"nctId":1003,"briefTitle":1004,"status":136,"phases":1225,"primaryCompletion":1006,"completion":1007,"start":1008,"enrollment":627,"conditions":1226,"interventions":1227},[89],[1010],[994,1012,1013,1014,1015,1016],{"trials":1229,"activeCount":98},[],{"trials":1231,"activeCount":98},[1232],{"nctId":1065,"briefTitle":1066,"status":136,"phases":1233,"primaryCompletion":1068,"completion":1068,"start":1069,"enrollment":1070,"conditions":1234,"interventions":1235},[91],[1072],[1074,1013,1012,1016],{"trials":1237,"activeCount":98},[],{"intervention":1016,"totalTrials":194,"cells":1239},{"EARLY_PHASE1":1240,"PHASE1":1242,"PHASE2":1244,"PHASE3":1250,"PHASE4":1252,"NA":1258},{"trials":1241,"activeCount":98},[],{"trials":1243,"activeCount":98},[],{"trials":1245,"activeCount":98},[1246],{"nctId":1003,"briefTitle":1004,"status":136,"phases":1247,"primaryCompletion":1006,"completion":1007,"start":1008,"enrollment":627,"conditions":1248,"interventions":1249},[89],[1010],[994,1012,1013,1014,1015,1016],{"trials":1251,"activeCount":98},[],{"trials":1253,"activeCount":98},[1254],{"nctId":1065,"briefTitle":1066,"status":136,"phases":1255,"primaryCompletion":1068,"completion":1068,"start":1069,"enrollment":1070,"conditions":1256,"interventions":1257},[91],[1072],[1074,1013,1012,1016],{"trials":1259,"activeCount":98},[],{"intervention":1261,"totalTrials":194,"cells":1262},"quetiapine and placebo",{"EARLY_PHASE1":1263,"PHASE1":1265,"PHASE2":1267,"PHASE3":1269,"PHASE4":1271,"NA":1294},{"trials":1264,"activeCount":98},[],{"trials":1266,"activeCount":98},[],{"trials":1268,"activeCount":98},[],{"trials":1270,"activeCount":98},[],{"trials":1272,"activeCount":98},[1273,1283],{"nctId":1274,"briefTitle":1275,"status":136,"phases":1276,"primaryCompletion":806,"completion":806,"start":1277,"enrollment":1278,"conditions":1279,"interventions":1281},"NCT00550394","Efficacy and Tolerability of Topiramate in Treatment of Bipolar Mania and Alcohol Use in Adolescents and Young Adults",[91],"2008-04",56,[21,1280],"Alcohol Abuse",[1261,1282],"Quetiapine and Topiramate",{"nctId":1284,"briefTitle":1285,"status":136,"phases":1286,"primaryCompletion":1287,"completion":169,"start":1288,"enrollment":1289,"conditions":1290,"interventions":1292},"NCT00393978","Efficacy Study of Quetiapine Plus Topiramate for Reducing Cannabis Consumption and Bipolar Mania",[91],"2011-12","2006-11",75,[21,1291],"Cannabis-Related Disorder",[1293,1282],"Quetiapine and placebo",{"trials":1295,"activeCount":98},[],{"intervention":1282,"totalTrials":194,"cells":1297},{"EARLY_PHASE1":1298,"PHASE1":1300,"PHASE2":1302,"PHASE3":1304,"PHASE4":1306,"NA":1316},{"trials":1299,"activeCount":98},[],{"trials":1301,"activeCount":98},[],{"trials":1303,"activeCount":98},[],{"trials":1305,"activeCount":98},[],{"trials":1307,"activeCount":98},[1308,1312],{"nctId":1274,"briefTitle":1275,"status":136,"phases":1309,"primaryCompletion":806,"completion":806,"start":1277,"enrollment":1278,"conditions":1310,"interventions":1311},[91],[21,1280],[1261,1282],{"nctId":1284,"briefTitle":1285,"status":136,"phases":1313,"primaryCompletion":1287,"completion":169,"start":1288,"enrollment":1289,"conditions":1314,"interventions":1315},[91],[21,1291],[1293,1282],{"trials":1317,"activeCount":98},[],{"intervention":1319,"totalTrials":194,"cells":1320},"Normal saline",{"EARLY_PHASE1":1321,"PHASE1":1335,"PHASE2":1337,"PHASE3":1339,"PHASE4":1341,"NA":1355},{"trials":1322,"activeCount":98},[1323],{"nctId":1324,"briefTitle":1325,"status":136,"phases":1326,"primaryCompletion":1327,"completion":1328,"start":1329,"enrollment":1330,"conditions":1331,"interventions":1333},"NCT05357079","Impact of Topical Tranexamic Acid on Pre- and Post-operative Hemoglobin\u002FHematocrit",[87],"2024-08-30","2024-12-02","2017-08-25",94,[1332],"Fracture of Posterior Wall of Acetabulum",[1334,1319],"Tranexamic Acid",{"trials":1336,"activeCount":98},[],{"trials":1338,"activeCount":98},[],{"trials":1340,"activeCount":98},[],{"trials":1342,"activeCount":98},[1343],{"nctId":1344,"briefTitle":1345,"status":136,"phases":1346,"primaryCompletion":1347,"completion":1347,"start":1348,"enrollment":1349,"conditions":1350,"interventions":1352},"NCT04860856","Efficacy of Hematoma Block on Postoperative Pain After Femoral Intramedullary Rodding: A Randomized Trial",[91],"2023-02-07","2019-08-17",88,[1351],"Femur Fracture",[1353,1354],"0.5% ropivacaine","Normal Saline",{"trials":1356,"activeCount":98},[],{"intervention":784,"totalTrials":194,"cells":1358},{"EARLY_PHASE1":1359,"PHASE1":1361,"PHASE2":1363,"PHASE3":1365,"PHASE4":1367,"NA":1377},{"trials":1360,"activeCount":98},[],{"trials":1362,"activeCount":98},[],{"trials":1364,"activeCount":98},[],{"trials":1366,"activeCount":98},[],{"trials":1368,"activeCount":98},[1369,1373],{"nctId":908,"briefTitle":909,"status":136,"phases":1370,"primaryCompletion":490,"completion":911,"start":912,"enrollment":913,"conditions":1371,"interventions":1372},[91],[915],[917,786,784,918,902,919],{"nctId":773,"briefTitle":774,"status":775,"phases":1374,"primaryCompletion":777,"completion":778,"start":779,"enrollment":780,"conditions":1375,"interventions":1376},[91],[782],[784,352,334,785,786],{"trials":1378,"activeCount":98},[],{"intervention":1380,"totalTrials":228,"cells":1381},"Exenatide",{"EARLY_PHASE1":1382,"PHASE1":1384,"PHASE2":1386,"PHASE3":1388,"PHASE4":1390,"NA":1402},{"trials":1383,"activeCount":98},[],{"trials":1385,"activeCount":98},[],{"trials":1387,"activeCount":98},[],{"trials":1389,"activeCount":98},[],{"trials":1391,"activeCount":98},[1392],{"nctId":1393,"briefTitle":1394,"status":136,"phases":1395,"primaryCompletion":1396,"completion":1396,"start":1397,"enrollment":1398,"conditions":1399,"interventions":1401},"NCT00845507","Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults",[91],"2015-07","2008-12",54,[1400],"Weight Gain",[1380],{"trials":1403,"activeCount":98},[],{"intervention":1405,"totalTrials":228,"cells":1406},"Lamotrigine Generic \"A\"",{"EARLY_PHASE1":1407,"PHASE1":1409,"PHASE2":1411,"PHASE3":1413,"PHASE4":1415,"NA":1428},{"trials":1408,"activeCount":98},[],{"trials":1410,"activeCount":98},[],{"trials":1412,"activeCount":98},[],{"trials":1414,"activeCount":98},[],{"trials":1416,"activeCount":98},[1417],{"nctId":1418,"briefTitle":1419,"status":136,"phases":1420,"primaryCompletion":1421,"completion":1421,"start":1422,"enrollment":1423,"conditions":1424,"interventions":1426},"NCT01713777","Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Chronic-Dose 4-Period Replicate Design",[91],"2015-09","2013-04",35,[1425],"Epilepsy",[1405,1427],"Lamotrigine generic \"B\"",{"trials":1429,"activeCount":98},[],{"intervention":1427,"totalTrials":228,"cells":1431},{"EARLY_PHASE1":1432,"PHASE1":1434,"PHASE2":1436,"PHASE3":1438,"PHASE4":1440,"NA":1446},{"trials":1433,"activeCount":98},[],{"trials":1435,"activeCount":98},[],{"trials":1437,"activeCount":98},[],{"trials":1439,"activeCount":98},[],{"trials":1441,"activeCount":98},[1442],{"nctId":1418,"briefTitle":1419,"status":136,"phases":1443,"primaryCompletion":1421,"completion":1421,"start":1422,"enrollment":1423,"conditions":1444,"interventions":1445},[91],[1425],[1405,1427],{"trials":1447,"activeCount":98},[],{"intervention":1449,"totalTrials":228,"cells":1450},"C-11 labeled nicotine",{"EARLY_PHASE1":1451,"PHASE1":1453,"PHASE2":1455,"PHASE3":1457,"PHASE4":1459,"NA":1471},{"trials":1452,"activeCount":98},[],{"trials":1454,"activeCount":98},[],{"trials":1456,"activeCount":98},[],{"trials":1458,"activeCount":98},[],{"trials":1460,"activeCount":98},[1461],{"nctId":1462,"briefTitle":1463,"status":775,"phases":1464,"primaryCompletion":1465,"completion":1466,"start":1467,"enrollment":194,"conditions":1468,"interventions":1470},"NCT03491059","Feasibility of PET\u002FCT to Detect the Oral\u002FPulmonary Distribution of Nicotine Following E-cigarette Use",[91],"2024-12-31","2025-02-16","2018-02-16",[1469],"E-cigarette Use",[1449],{"trials":1472,"activeCount":98},[],{"intervention":1474,"totalTrials":228,"cells":1475},"Botulinum Toxin Type A",{"EARLY_PHASE1":1476,"PHASE1":1478,"PHASE2":1480,"PHASE3":1482,"PHASE4":1484,"NA":1495},{"trials":1477,"activeCount":98},[],{"trials":1479,"activeCount":98},[],{"trials":1481,"activeCount":98},[],{"trials":1483,"activeCount":98},[],{"trials":1485,"activeCount":98},[1486],{"nctId":1487,"briefTitle":1488,"status":756,"phases":1489,"primaryCompletion":1490,"completion":1397,"start":1491,"enrollment":25,"conditions":1492,"interventions":1494},"NCT00477802","Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease",[91],"2008-11","2007-05",[1493],"Parkinson Disease",[1474],{"trials":1496,"activeCount":98},[],{"intervention":1074,"totalTrials":228,"cells":1498},{"EARLY_PHASE1":1499,"PHASE1":1501,"PHASE2":1503,"PHASE3":1505,"PHASE4":1507,"NA":1513},{"trials":1500,"activeCount":98},[],{"trials":1502,"activeCount":98},[],{"trials":1504,"activeCount":98},[],{"trials":1506,"activeCount":98},[],{"trials":1508,"activeCount":98},[1509],{"nctId":1065,"briefTitle":1066,"status":136,"phases":1510,"primaryCompletion":1068,"completion":1068,"start":1069,"enrollment":1070,"conditions":1511,"interventions":1512},[91],[1072],[1074,1013,1012,1016],{"trials":1514,"activeCount":98},[],{"intervention":1516,"totalTrials":228,"cells":1517},"Ropivacaine",{"EARLY_PHASE1":1518,"PHASE1":1520,"PHASE2":1522,"PHASE3":1524,"PHASE4":1526,"NA":1541},{"trials":1519,"activeCount":98},[],{"trials":1521,"activeCount":98},[],{"trials":1523,"activeCount":98},[],{"trials":1525,"activeCount":98},[],{"trials":1527,"activeCount":98},[1528],{"nctId":1529,"briefTitle":1530,"status":136,"phases":1531,"primaryCompletion":1532,"completion":1533,"start":1534,"enrollment":1535,"conditions":1536,"interventions":1540},"NCT02950558","Anesthesia for Pain After Ankle Fracture Surgery",[91],"2019-11-14","2020-06-19","2018-05-29",14,[1537,1538,1539],"Chronic Pain","Ankle Fracture Surgery","Regional Anesthesia",[1516],{"trials":1542,"activeCount":98},[],{"intervention":1544,"totalTrials":228,"cells":1545},"Acthar gel",{"EARLY_PHASE1":1546,"PHASE1":1548,"PHASE2":1550,"PHASE3":1552,"PHASE4":1554,"NA":1566},{"trials":1547,"activeCount":98},[],{"trials":1549,"activeCount":98},[],{"trials":1551,"activeCount":98},[],{"trials":1553,"activeCount":98},[],{"trials":1555,"activeCount":98},[1556],{"nctId":1557,"briefTitle":1558,"status":775,"phases":1559,"primaryCompletion":1560,"completion":1561,"start":1562,"enrollment":328,"conditions":1563,"interventions":1565},"NCT02188017","Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS)",[91],"2016-12","2017-09","2014-06",[18,1564],"Pulmonary Sarcoidosis",[1544],{"trials":1567,"activeCount":98},[],{"intervention":1569,"totalTrials":228,"cells":1570},"Thymoglobulin",{"EARLY_PHASE1":1571,"PHASE1":1573,"PHASE2":1575,"PHASE3":1577,"PHASE4":1579,"NA":1591},{"trials":1572,"activeCount":98},[],{"trials":1574,"activeCount":98},[],{"trials":1576,"activeCount":98},[],{"trials":1578,"activeCount":98},[],{"trials":1580,"activeCount":98},[1581],{"nctId":1582,"briefTitle":1583,"status":136,"phases":1584,"primaryCompletion":806,"completion":1585,"start":1008,"enrollment":1586,"conditions":1587,"interventions":1590},"NCT00771745","Prospective Pilot Study of Pre-Transplant Thymoglobulin Administration in Living Donor Renal Transplant Recipients",[91],"2010-07",11,[1588,1589],"Renal Transplant Rejection","Transplants and Implants",[1569,1569],{"trials":1592,"activeCount":98},[],{"intervention":1594,"totalTrials":228,"cells":1595},"Divalproex ER",{"EARLY_PHASE1":1596,"PHASE1":1598,"PHASE2":1600,"PHASE3":1602,"PHASE4":1604,"NA":1617},{"trials":1597,"activeCount":98},[],{"trials":1599,"activeCount":98},[],{"trials":1601,"activeCount":98},[],{"trials":1603,"activeCount":98},[],{"trials":1605,"activeCount":98},[1606],{"nctId":1607,"briefTitle":1608,"status":503,"phases":1609,"completion":1610,"start":181,"enrollment":98,"conditions":1611,"interventions":1615},"NCT00375557","Safety and Efficacy of Divalproex and Quetiapine in Elderly Alzheimer's Dementia Patients",[91],"2007-09",[1612,1613,1614],"Alzheimer's Disease","Dementia","Behavioral Symptoms",[1594,1616],"Quetiapine",{"trials":1618,"activeCount":98},[],{"intervention":1620,"totalTrials":228,"cells":1621},"Metoprolol Succinate",{"EARLY_PHASE1":1622,"PHASE1":1624,"PHASE2":1626,"PHASE3":1628,"PHASE4":1630,"NA":1641},{"trials":1623,"activeCount":98},[],{"trials":1625,"activeCount":98},[],{"trials":1627,"activeCount":98},[],{"trials":1629,"activeCount":98},[],{"trials":1631,"activeCount":98},[1632],{"nctId":1633,"briefTitle":1634,"status":756,"phases":1635,"primaryCompletion":1636,"completion":1636,"start":1637,"enrollment":393,"conditions":1638,"interventions":1640},"NCT00491387","Sympathetic Nervous System Modulation in Hypertension",[91],"2009-01","2007-08",[1639],"Hypertension",[1620],{"trials":1642,"activeCount":98},[],{"intervention":1098,"totalTrials":228,"cells":1644},{"EARLY_PHASE1":1645,"PHASE1":1647,"PHASE2":1649,"PHASE3":1651,"PHASE4":1653,"NA":1659},{"trials":1646,"activeCount":98},[],{"trials":1648,"activeCount":98},[],{"trials":1650,"activeCount":98},[],{"trials":1652,"activeCount":98},[],{"trials":1654,"activeCount":98},[1655],{"nctId":1090,"briefTitle":1091,"status":136,"phases":1656,"primaryCompletion":1093,"completion":1093,"start":348,"enrollment":1094,"conditions":1657,"interventions":1658},[91],[1096],[901,1098,1099,1100,1101,1102],{"trials":1660,"activeCount":98},[],{"intervention":1099,"totalTrials":228,"cells":1662},{"EARLY_PHASE1":1663,"PHASE1":1665,"PHASE2":1667,"PHASE3":1669,"PHASE4":1671,"NA":1677},{"trials":1664,"activeCount":98},[],{"trials":1666,"activeCount":98},[],{"trials":1668,"activeCount":98},[],{"trials":1670,"activeCount":98},[],{"trials":1672,"activeCount":98},[1673],{"nctId":1090,"briefTitle":1091,"status":136,"phases":1674,"primaryCompletion":1093,"completion":1093,"start":348,"enrollment":1094,"conditions":1675,"interventions":1676},[91],[1096],[901,1098,1099,1100,1101,1102],{"trials":1678,"activeCount":98},[],{"intervention":1100,"totalTrials":228,"cells":1680},{"EARLY_PHASE1":1681,"PHASE1":1683,"PHASE2":1685,"PHASE3":1687,"PHASE4":1689,"NA":1695},{"trials":1682,"activeCount":98},[],{"trials":1684,"activeCount":98},[],{"trials":1686,"activeCount":98},[],{"trials":1688,"activeCount":98},[],{"trials":1690,"activeCount":98},[1691],{"nctId":1090,"briefTitle":1091,"status":136,"phases":1692,"primaryCompletion":1093,"completion":1093,"start":348,"enrollment":1094,"conditions":1693,"interventions":1694},[91],[1096],[901,1098,1099,1100,1101,1102],{"trials":1696,"activeCount":98},[],{"intervention":1101,"totalTrials":228,"cells":1698},{"EARLY_PHASE1":1699,"PHASE1":1701,"PHASE2":1703,"PHASE3":1705,"PHASE4":1707,"NA":1713},{"trials":1700,"activeCount":98},[],{"trials":1702,"activeCount":98},[],{"trials":1704,"activeCount":98},[],{"trials":1706,"activeCount":98},[],{"trials":1708,"activeCount":98},[1709],{"nctId":1090,"briefTitle":1091,"status":136,"phases":1710,"primaryCompletion":1093,"completion":1093,"start":348,"enrollment":1094,"conditions":1711,"interventions":1712},[91],[1096],[901,1098,1099,1100,1101,1102],{"trials":1714,"activeCount":98},[],{"intervention":1102,"totalTrials":228,"cells":1716},{"EARLY_PHASE1":1717,"PHASE1":1719,"PHASE2":1721,"PHASE3":1723,"PHASE4":1725,"NA":1731},{"trials":1718,"activeCount":98},[],{"trials":1720,"activeCount":98},[],{"trials":1722,"activeCount":98},[],{"trials":1724,"activeCount":98},[],{"trials":1726,"activeCount":98},[1727],{"nctId":1090,"briefTitle":1091,"status":136,"phases":1728,"primaryCompletion":1093,"completion":1093,"start":348,"enrollment":1094,"conditions":1729,"interventions":1730},[91],[1096],[901,1098,1099,1100,1101,1102],{"trials":1732,"activeCount":98},[],{"intervention":332,"totalTrials":228,"cells":1734},{"EARLY_PHASE1":1735,"PHASE1":1737,"PHASE2":1739,"PHASE3":1741,"PHASE4":1743,"NA":1749},{"trials":1736,"activeCount":98},[],{"trials":1738,"activeCount":98},[],{"trials":1740,"activeCount":98},[],{"trials":1742,"activeCount":98},[],{"trials":1744,"activeCount":98},[1745],{"nctId":323,"briefTitle":324,"status":136,"phases":1746,"primaryCompletion":326,"completion":326,"start":327,"enrollment":328,"conditions":1747,"interventions":1748},[91],[330],[332,333,334],{"trials":1750,"activeCount":98},[],{"intervention":1752,"totalTrials":228,"cells":1753},"d-methylphenidate",{"EARLY_PHASE1":1754,"PHASE1":1756,"PHASE2":1758,"PHASE3":1760,"PHASE4":1762,"NA":1771},{"trials":1755,"activeCount":98},[],{"trials":1757,"activeCount":98},[],{"trials":1759,"activeCount":98},[],{"trials":1761,"activeCount":98},[],{"trials":1763,"activeCount":98},[1764],{"nctId":1765,"briefTitle":1766,"status":136,"phases":1767,"primaryCompletion":950,"completion":928,"start":1768,"enrollment":22,"conditions":1769,"interventions":1770},"NCT00361387","Use of Focalin for Fatigue in Sarcoidosis",[91],"2006-06",[18],[1752],{"trials":1772,"activeCount":98},[],{"intervention":1774,"totalTrials":228,"cells":1775},"Roflumilast",{"EARLY_PHASE1":1776,"PHASE1":1778,"PHASE2":1780,"PHASE3":1782,"PHASE4":1784,"NA":1794},{"trials":1777,"activeCount":98},[],{"trials":1779,"activeCount":98},[],{"trials":1781,"activeCount":98},[],{"trials":1783,"activeCount":98},[],{"trials":1785,"activeCount":98},[1786],{"nctId":1787,"briefTitle":1788,"status":775,"phases":1789,"primaryCompletion":1790,"completion":1791,"start":1422,"enrollment":468,"conditions":1792,"interventions":1793},"NCT01830959","Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS)",[91],"2016-05","2016-10",[18],[1774],{"trials":1795,"activeCount":98},[],{"intervention":1797,"totalTrials":228,"cells":1798},"Riociguat",{"EARLY_PHASE1":1799,"PHASE1":1801,"PHASE2":1803,"PHASE3":1805,"PHASE4":1807,"NA":1818},{"trials":1800,"activeCount":98},[],{"trials":1802,"activeCount":98},[],{"trials":1804,"activeCount":98},[],{"trials":1806,"activeCount":98},[],{"trials":1808,"activeCount":98},[1809],{"nctId":1810,"briefTitle":1811,"status":775,"phases":1812,"primaryCompletion":1813,"completion":1814,"start":1815,"enrollment":8,"conditions":1816,"interventions":1817},"NCT02625558","Riociguat for Sarcoidosis Associated Pulmonary Hypertension",[91],"2018-04","2018-10","2015-04",[18],[1797],{"trials":1819,"activeCount":98},[],{"intervention":1821,"totalTrials":228,"cells":1822},"Iloprost",{"EARLY_PHASE1":1823,"PHASE1":1825,"PHASE2":1827,"PHASE3":1829,"PHASE4":1831,"NA":1841},{"trials":1824,"activeCount":98},[],{"trials":1826,"activeCount":98},[],{"trials":1828,"activeCount":98},[],{"trials":1830,"activeCount":98},[],{"trials":1832,"activeCount":98},[1833],{"nctId":1834,"briefTitle":1835,"status":136,"phases":1836,"primaryCompletion":1837,"completion":1008,"start":1288,"enrollment":328,"conditions":1838,"interventions":1840},"NCT00403650","Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension",[91],"2008-07",[18,1839],"Pulmonary Arterial Hypertension",[1821],{"trials":1842,"activeCount":98},[],{"intervention":1029,"totalTrials":228,"cells":1844},{"EARLY_PHASE1":1845,"PHASE1":1847,"PHASE2":1849,"PHASE3":1851,"PHASE4":1853,"NA":1859},{"trials":1846,"activeCount":98},[],{"trials":1848,"activeCount":98},[],{"trials":1850,"activeCount":98},[],{"trials":1852,"activeCount":98},[],{"trials":1854,"activeCount":98},[1855],{"nctId":1022,"briefTitle":1023,"status":136,"phases":1856,"primaryCompletion":1025,"completion":1007,"start":1008,"enrollment":182,"conditions":1857,"interventions":1858},[91],[1027],[994,1029,1030],{"trials":1860,"activeCount":98},[],{"intervention":1030,"totalTrials":228,"cells":1862},{"EARLY_PHASE1":1863,"PHASE1":1865,"PHASE2":1867,"PHASE3":1869,"PHASE4":1871,"NA":1877},{"trials":1864,"activeCount":98},[],{"trials":1866,"activeCount":98},[],{"trials":1868,"activeCount":98},[],{"trials":1870,"activeCount":98},[],{"trials":1872,"activeCount":98},[1873],{"nctId":1022,"briefTitle":1023,"status":136,"phases":1874,"primaryCompletion":1025,"completion":1007,"start":1008,"enrollment":182,"conditions":1875,"interventions":1876},[91],[1027],[994,1029,1030],{"trials":1878,"activeCount":98},[],{"intervention":1880,"totalTrials":228,"cells":1881},"Ceftaroline",{"EARLY_PHASE1":1882,"PHASE1":1884,"PHASE2":1886,"PHASE3":1888,"PHASE4":1890,"NA":1903},{"trials":1883,"activeCount":98},[],{"trials":1885,"activeCount":98},[],{"trials":1887,"activeCount":98},[],{"trials":1889,"activeCount":98},[],{"trials":1891,"activeCount":98},[1892],{"nctId":1893,"briefTitle":1894,"status":775,"phases":1895,"primaryCompletion":1560,"completion":1896,"start":1897,"enrollment":1898,"conditions":1899,"interventions":1901},"NCT02307006","The Use of Ceftaroline as Surgical Prophylaxis in Surgery With Risk of MRSA Infection",[91],"2017-06","2015-01",500,[1900],"Surgical Site Infection",[1880,1902],"Cefazolin \u002F Vancomycin",{"trials":1904,"activeCount":98},[],{"intervention":1902,"totalTrials":228,"cells":1906},{"EARLY_PHASE1":1907,"PHASE1":1909,"PHASE2":1911,"PHASE3":1913,"PHASE4":1915,"NA":1921},{"trials":1908,"activeCount":98},[],{"trials":1910,"activeCount":98},[],{"trials":1912,"activeCount":98},[],{"trials":1914,"activeCount":98},[],{"trials":1916,"activeCount":98},[1917],{"nctId":1893,"briefTitle":1894,"status":775,"phases":1918,"primaryCompletion":1560,"completion":1896,"start":1897,"enrollment":1898,"conditions":1919,"interventions":1920},[91],[1900],[1880,1902],{"trials":1922,"activeCount":98},[],{"intervention":1924,"totalTrials":228,"cells":1925},"Bismuth Subsalicylate 262 milligram (mg) Oral Tablet, Chewable",{"EARLY_PHASE1":1926,"PHASE1":1928,"PHASE2":1930,"PHASE3":1932,"PHASE4":1934,"NA":1945},{"trials":1927,"activeCount":98},[],{"trials":1929,"activeCount":98},[],{"trials":1931,"activeCount":98},[],{"trials":1933,"activeCount":98},[],{"trials":1935,"activeCount":98},[1936],{"nctId":1937,"briefTitle":1938,"status":136,"phases":1939,"primaryCompletion":1940,"completion":1940,"start":1941,"enrollment":8,"conditions":1942,"interventions":1944},"NCT04811339","Studies of COVID-19 Patients Treated With Oral Bismuth Subsalicylate (Pepto-Bismol)",[91],"2021-08-15","2020-10-27",[1943,299],"Diarrhea",[1924],{"trials":1946,"activeCount":98},[],{"intervention":900,"totalTrials":228,"cells":1948},{"EARLY_PHASE1":1949,"PHASE1":1951,"PHASE2":1953,"PHASE3":1955,"PHASE4":1957,"NA":1963},{"trials":1950,"activeCount":98},[],{"trials":1952,"activeCount":98},[],{"trials":1954,"activeCount":98},[],{"trials":1956,"activeCount":98},[],{"trials":1958,"activeCount":98},[1959],{"nctId":891,"briefTitle":892,"status":136,"phases":1960,"primaryCompletion":894,"completion":894,"start":895,"enrollment":896,"conditions":1961,"interventions":1962},[91],[898],[900,901,902],{"trials":1964,"activeCount":98},[],{"intervention":1353,"totalTrials":228,"cells":1966},{"EARLY_PHASE1":1967,"PHASE1":1969,"PHASE2":1971,"PHASE3":1973,"PHASE4":1975,"NA":1981},{"trials":1968,"activeCount":98},[],{"trials":1970,"activeCount":98},[],{"trials":1972,"activeCount":98},[],{"trials":1974,"activeCount":98},[],{"trials":1976,"activeCount":98},[1977],{"nctId":1344,"briefTitle":1345,"status":136,"phases":1978,"primaryCompletion":1347,"completion":1347,"start":1348,"enrollment":1349,"conditions":1979,"interventions":1980},[91],[1351],[1353,1354],{"trials":1982,"activeCount":98},[],{"intervention":1984,"totalTrials":228,"cells":1985},"Topiramate",{"EARLY_PHASE1":1986,"PHASE1":1988,"PHASE2":1990,"PHASE3":1992,"PHASE4":1994,"NA":2004},{"trials":1987,"activeCount":98},[],{"trials":1989,"activeCount":98},[],{"trials":1991,"activeCount":98},[],{"trials":1993,"activeCount":98},[],{"trials":1995,"activeCount":98},[1996],{"nctId":1997,"briefTitle":1998,"status":136,"phases":1999,"primaryCompletion":505,"completion":2000,"start":316,"enrollment":2001,"conditions":2002,"interventions":2003},"NCT00394095","Topiramate vs. Placebo in Preventing Weight Gain in Bipolar Disorder Treated With Olanzapine",[91],"2009-09",31,[21,1400],[1984],{"trials":2005,"activeCount":98},[],{"intervention":2007,"totalTrials":228,"cells":2008},"Ketorolac",{"EARLY_PHASE1":2009,"PHASE1":2011,"PHASE2":2013,"PHASE3":2015,"PHASE4":2017,"NA":2028},{"trials":2010,"activeCount":98},[],{"trials":2012,"activeCount":98},[],{"trials":2014,"activeCount":98},[],{"trials":2016,"activeCount":98},[],{"trials":2018,"activeCount":98},[2019],{"nctId":2020,"briefTitle":2021,"status":775,"phases":2022,"primaryCompletion":2023,"completion":139,"start":2024,"enrollment":8,"conditions":2025,"interventions":2027},"NCT04282200","Ketorolac in Acute Pancreatitis",[91],"2021-12","2020-02-24",[2026],"Acute Pancreatitis",[2007],{"trials":2029,"activeCount":98},[],{"intervention":2031,"totalTrials":228,"cells":2032},"Thalidomide",{"EARLY_PHASE1":2033,"PHASE1":2035,"PHASE2":2037,"PHASE3":2039,"PHASE4":2041,"NA":2053},{"trials":2034,"activeCount":98},[],{"trials":2036,"activeCount":98},[],{"trials":2038,"activeCount":98},[],{"trials":2040,"activeCount":98},[],{"trials":2042,"activeCount":98},[2043],{"nctId":2044,"briefTitle":2045,"status":756,"phases":2046,"completion":2047,"start":2048,"enrollment":2049,"conditions":2050,"interventions":2052},"NCT00314665","Use of Thalidomide in Chronic Uveitis",[91],"2006-08","2004-01",15,[2051],"Uveitis",[2031],{"trials":2054,"activeCount":98},[],{"intervention":2056,"totalTrials":228,"cells":2057},"mixed amphetamine salts-extended release",{"EARLY_PHASE1":2058,"PHASE1":2060,"PHASE2":2062,"PHASE3":2064,"PHASE4":2066,"NA":2077},{"trials":2059,"activeCount":98},[],{"trials":2061,"activeCount":98},[],{"trials":2063,"activeCount":98},[],{"trials":2065,"activeCount":98},[],{"trials":2067,"activeCount":98},[2068],{"nctId":2069,"briefTitle":2070,"status":136,"phases":2071,"primaryCompletion":2072,"completion":139,"start":2073,"enrollment":2074,"conditions":2075,"interventions":2076},"NCT02478788","Neuroimaging Study of Risk Factors for Adolescent Bipolar Disorder",[91],"2022-08","2015-11",153,[953],[2056],{"trials":2078,"activeCount":98},[],{"intervention":2080,"totalTrials":228,"cells":2081},"Daptomycin",{"EARLY_PHASE1":2082,"PHASE1":2084,"PHASE2":2086,"PHASE3":2088,"PHASE4":2090,"NA":2104},{"trials":2083,"activeCount":98},[],{"trials":2085,"activeCount":98},[],{"trials":2087,"activeCount":98},[],{"trials":2089,"activeCount":98},[],{"trials":2091,"activeCount":98},[2092],{"nctId":2093,"briefTitle":2094,"status":136,"phases":2095,"primaryCompletion":2096,"completion":2096,"start":2097,"enrollment":2098,"conditions":2099,"interventions":2102},"NCT01549613","Evaluation of Daptomycin for the Emergency Department Treatment of Complicated Skin and Skin Structure Infections",[91],"2013-07","2012-05",104,[2100,2101],"Cellulitis","Skin Infections",[2080,2103],"Vancomycin",{"trials":2105,"activeCount":98},[],{"intervention":2103,"totalTrials":228,"cells":2107},{"EARLY_PHASE1":2108,"PHASE1":2110,"PHASE2":2112,"PHASE3":2114,"PHASE4":2116,"NA":2122},{"trials":2109,"activeCount":98},[],{"trials":2111,"activeCount":98},[],{"trials":2113,"activeCount":98},[],{"trials":2115,"activeCount":98},[],{"trials":2117,"activeCount":98},[2118],{"nctId":2093,"briefTitle":2094,"status":136,"phases":2119,"primaryCompletion":2096,"completion":2096,"start":2097,"enrollment":2098,"conditions":2120,"interventions":2121},[91],[2100,2101],[2080,2103],{"trials":2123,"activeCount":98},[],{"intervention":2125,"totalTrials":228,"cells":2126},"Truvada",{"EARLY_PHASE1":2127,"PHASE1":2129,"PHASE2":2131,"PHASE3":2133,"PHASE4":2135,"NA":2147},{"trials":2128,"activeCount":98},[],{"trials":2130,"activeCount":98},[],{"trials":2132,"activeCount":98},[],{"trials":2134,"activeCount":98},[],{"trials":2136,"activeCount":98},[2137],{"nctId":2138,"briefTitle":2139,"status":136,"phases":2140,"primaryCompletion":2000,"completion":2141,"start":2142,"enrollment":8,"conditions":2143,"interventions":2145},"NCT00885664","Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection",[91],"2010-03","2005-10",[2144],"HIV Infections",[2125,2146],"Kaletra",{"trials":2148,"activeCount":98},[],{"intervention":2146,"totalTrials":228,"cells":2150},{"EARLY_PHASE1":2151,"PHASE1":2153,"PHASE2":2155,"PHASE3":2157,"PHASE4":2159,"NA":2165},{"trials":2152,"activeCount":98},[],{"trials":2154,"activeCount":98},[],{"trials":2156,"activeCount":98},[],{"trials":2158,"activeCount":98},[],{"trials":2160,"activeCount":98},[2161],{"nctId":2138,"briefTitle":2139,"status":136,"phases":2162,"primaryCompletion":2000,"completion":2141,"start":2142,"enrollment":8,"conditions":2163,"interventions":2164},[91],[2144],[2125,2146],{"trials":2166,"activeCount":98},[],{"intervention":2168,"totalTrials":228,"cells":2169},"Pantoprazole",{"EARLY_PHASE1":2170,"PHASE1":2172,"PHASE2":2174,"PHASE3":2176,"PHASE4":2178,"NA":2190},{"trials":2171,"activeCount":98},[],{"trials":2173,"activeCount":98},[],{"trials":2175,"activeCount":98},[],{"trials":2177,"activeCount":98},[],{"trials":2179,"activeCount":98},[2180],{"nctId":2181,"briefTitle":2182,"status":136,"phases":2183,"completion":2047,"start":2184,"enrollment":2185,"conditions":2186,"interventions":2189},"NCT00307944","Study of Pantoprazole for Sleepiness Associated With Acid Reflux and Sleep Apnea",[91],"2004-08",68,[2187,2188],"Acid Reflux Disease","Obstructive Sleep Apnea",[2168],{"trials":2191,"activeCount":98},[],{"intervention":917,"totalTrials":228,"cells":2193},{"EARLY_PHASE1":2194,"PHASE1":2196,"PHASE2":2198,"PHASE3":2200,"PHASE4":2202,"NA":2208},{"trials":2195,"activeCount":98},[],{"trials":2197,"activeCount":98},[],{"trials":2199,"activeCount":98},[],{"trials":2201,"activeCount":98},[],{"trials":2203,"activeCount":98},[2204],{"nctId":908,"briefTitle":909,"status":136,"phases":2205,"primaryCompletion":490,"completion":911,"start":912,"enrollment":913,"conditions":2206,"interventions":2207},[91],[915],[917,786,784,918,902,919],{"trials":2209,"activeCount":98},[],{"intervention":919,"totalTrials":228,"cells":2211},{"EARLY_PHASE1":2212,"PHASE1":2214,"PHASE2":2216,"PHASE3":2218,"PHASE4":2220,"NA":2226},{"trials":2213,"activeCount":98},[],{"trials":2215,"activeCount":98},[],{"trials":2217,"activeCount":98},[],{"trials":2219,"activeCount":98},[],{"trials":2221,"activeCount":98},[2222],{"nctId":908,"briefTitle":909,"status":136,"phases":2223,"primaryCompletion":490,"completion":911,"start":912,"enrollment":913,"conditions":2224,"interventions":2225},[91],[915],[917,786,784,918,902,919],{"trials":2227,"activeCount":98},[],{"intervention":2229,"totalTrials":228,"cells":2230},"Nicotine Nasal Spray",{"EARLY_PHASE1":2231,"PHASE1":2233,"PHASE2":2235,"PHASE3":2237,"PHASE4":2239,"NA":2251},{"trials":2232,"activeCount":98},[],{"trials":2234,"activeCount":98},[],{"trials":2236,"activeCount":98},[],{"trials":2238,"activeCount":98},[],{"trials":2240,"activeCount":98},[2241],{"nctId":2242,"briefTitle":2243,"status":756,"phases":2244,"primaryCompletion":1329,"completion":1329,"start":2245,"enrollment":28,"conditions":2246,"interventions":2249},"NCT02147132","Pilot Study of Nicotine Nasal Spray and Varenicline on Smoking in Methadone-Maintained Patients",[91],"2016-03",[2247,2248],"Cigarette Smoking","Methadone Maintenance",[2229,2250],"Varenicline",{"trials":2252,"activeCount":98},[],{"intervention":2250,"totalTrials":228,"cells":2254},{"EARLY_PHASE1":2255,"PHASE1":2257,"PHASE2":2259,"PHASE3":2261,"PHASE4":2263,"NA":2269},{"trials":2256,"activeCount":98},[],{"trials":2258,"activeCount":98},[],{"trials":2260,"activeCount":98},[],{"trials":2262,"activeCount":98},[],{"trials":2264,"activeCount":98},[2265],{"nctId":2242,"briefTitle":2243,"status":756,"phases":2266,"primaryCompletion":1329,"completion":1329,"start":2245,"enrollment":28,"conditions":2267,"interventions":2268},[91],[2247,2248],[2229,2250],{"trials":2270,"activeCount":98},[],{"intervention":2272,"totalTrials":228,"cells":2273},"nasal diazepam",{"EARLY_PHASE1":2274,"PHASE1":2276,"PHASE2":2278,"PHASE3":2280,"PHASE4":2282,"NA":2293},{"trials":2275,"activeCount":98},[],{"trials":2277,"activeCount":98},[],{"trials":2279,"activeCount":98},[],{"trials":2281,"activeCount":98},[],{"trials":2283,"activeCount":98},[2284],{"nctId":2285,"briefTitle":2286,"status":136,"phases":2287,"primaryCompletion":2288,"completion":2288,"start":2289,"enrollment":154,"conditions":2290,"interventions":2292},"NCT05273398","Effects of Diazepam on RNS Detections",[91],"2022-11-10","2022-03-01",[2291],"Epilepsies, Partial",[2272],{"trials":2294,"activeCount":98},[],{"intervention":2296,"totalTrials":228,"cells":2297},"Lamotrigine Generic \"A\" Lamotrigine Generic \"B\" Lamotrigine \"Brand\"",{"EARLY_PHASE1":2298,"PHASE1":2300,"PHASE2":2302,"PHASE3":2304,"PHASE4":2306,"NA":2317},{"trials":2299,"activeCount":98},[],{"trials":2301,"activeCount":98},[],{"trials":2303,"activeCount":98},[],{"trials":2305,"activeCount":98},[],{"trials":2307,"activeCount":98},[2308],{"nctId":2309,"briefTitle":2310,"status":136,"phases":2311,"primaryCompletion":2312,"completion":2312,"start":2313,"enrollment":1398,"conditions":2314,"interventions":2315},"NCT01733394","Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Single-Dose 6-Period Replicate Design (EQUIGEN Single-Dose Study)",[91],"2016-09-26","2012-12-12",[1425],[2296,2316],"lamotrigine",{"trials":2318,"activeCount":98},[],{"intervention":2316,"totalTrials":228,"cells":2320},{"EARLY_PHASE1":2321,"PHASE1":2323,"PHASE2":2325,"PHASE3":2327,"PHASE4":2329,"NA":2335},{"trials":2322,"activeCount":98},[],{"trials":2324,"activeCount":98},[],{"trials":2326,"activeCount":98},[],{"trials":2328,"activeCount":98},[],{"trials":2330,"activeCount":98},[2331],{"nctId":2309,"briefTitle":2310,"status":136,"phases":2332,"primaryCompletion":2312,"completion":2312,"start":2313,"enrollment":1398,"conditions":2333,"interventions":2334},[91],[1425],[2296,2316],{"trials":2336,"activeCount":98},[],{"intervention":2338,"totalTrials":228,"cells":2339},"Enoxaparin 40 mg q12h",{"EARLY_PHASE1":2340,"PHASE1":2342,"PHASE2":2344,"PHASE3":2346,"PHASE4":2348,"NA":2361},{"trials":2341,"activeCount":98},[],{"trials":2343,"activeCount":98},[],{"trials":2345,"activeCount":98},[],{"trials":2347,"activeCount":98},[],{"trials":2349,"activeCount":98},[2350],{"nctId":2351,"briefTitle":2352,"status":136,"phases":2353,"primaryCompletion":2354,"completion":2354,"start":2245,"enrollment":2355,"conditions":2356,"interventions":2359},"NCT02412982","Evaluation of Venous Thromboembolism Prevention in High-Risk Trauma Patients",[91],"2019-01",103,[2357,2358],"Traumatic Injury","Venous Thromboembolism",[2338,2360],"Enoxaparin 30 mg q8h",{"trials":2362,"activeCount":98},[],{"intervention":2360,"totalTrials":228,"cells":2364},{"EARLY_PHASE1":2365,"PHASE1":2367,"PHASE2":2369,"PHASE3":2371,"PHASE4":2373,"NA":2379},{"trials":2366,"activeCount":98},[],{"trials":2368,"activeCount":98},[],{"trials":2370,"activeCount":98},[],{"trials":2372,"activeCount":98},[],{"trials":2374,"activeCount":98},[2375],{"nctId":2351,"briefTitle":2352,"status":136,"phases":2376,"primaryCompletion":2354,"completion":2354,"start":2245,"enrollment":2355,"conditions":2377,"interventions":2378},[91],[2357,2358],[2338,2360],{"trials":2380,"activeCount":98},[],{"intervention":785,"totalTrials":228,"cells":2382},{"EARLY_PHASE1":2383,"PHASE1":2385,"PHASE2":2387,"PHASE3":2389,"PHASE4":2391,"NA":2397},{"trials":2384,"activeCount":98},[],{"trials":2386,"activeCount":98},[],{"trials":2388,"activeCount":98},[],{"trials":2390,"activeCount":98},[],{"trials":2392,"activeCount":98},[2393],{"nctId":773,"briefTitle":774,"status":775,"phases":2394,"primaryCompletion":777,"completion":778,"start":779,"enrollment":780,"conditions":2395,"interventions":2396},[91],[782],[784,352,334,785,786],{"trials":2398,"activeCount":98},[],{"intervention":2400,"totalTrials":228,"cells":2401},"Eplerenone 50 Mg Tab",{"EARLY_PHASE1":2402,"PHASE1":2404,"PHASE2":2406,"PHASE3":2408,"PHASE4":2410,"NA":2423},{"trials":2403,"activeCount":98},[],{"trials":2405,"activeCount":98},[],{"trials":2407,"activeCount":98},[],{"trials":2409,"activeCount":98},[],{"trials":2411,"activeCount":98},[2412],{"nctId":2413,"briefTitle":2414,"status":503,"phases":2415,"primaryCompletion":70,"completion":2416,"start":2417,"enrollment":98,"conditions":2418,"interventions":2422},"NCT03418649","Eplerenone as a Supplement to Epidural Steroid Injections",[91],"2026-06","2023-06",[2419,2420,2421],"Degenerative Intervertebral Discs","Sciatic Radiculopathy","Low Back Pain",[2400],{"trials":2424,"activeCount":98},[],{"intervention":2426,"totalTrials":228,"cells":2427},"Trigger Point Injections Triamcinolone Acetonide, Bupivacaine Hydrochloride",{"EARLY_PHASE1":2428,"PHASE1":2430,"PHASE2":2432,"PHASE3":2434,"PHASE4":2436,"NA":2447},{"trials":2429,"activeCount":98},[],{"trials":2431,"activeCount":98},[],{"trials":2433,"activeCount":98},[],{"trials":2435,"activeCount":98},[],{"trials":2437,"activeCount":98},[2438],{"nctId":2439,"briefTitle":2440,"status":775,"phases":2441,"primaryCompletion":1172,"completion":1562,"start":2442,"enrollment":2443,"conditions":2444,"interventions":2446},"NCT02022722","Trigger Point Injections and Pelvic Rehabilitation for the Treatment of Pelvic Floor Myalgia and Sexual Pain",[91],"2013-08",36,[2445],"Dyspareunia",[2426],{"trials":2448,"activeCount":98},[],{"intervention":934,"totalTrials":228,"cells":2450},{"EARLY_PHASE1":2451,"PHASE1":2453,"PHASE2":2455,"PHASE3":2457,"PHASE4":2459,"NA":2465},{"trials":2452,"activeCount":98},[],{"trials":2454,"activeCount":98},[],{"trials":2456,"activeCount":98},[],{"trials":2458,"activeCount":98},[],{"trials":2460,"activeCount":98},[2461],{"nctId":925,"briefTitle":926,"status":136,"phases":2462,"primaryCompletion":928,"completion":928,"start":929,"enrollment":182,"conditions":2463,"interventions":2464},[91],[931],[933,334,934],{"trials":2466,"activeCount":98},[],{"intervention":2468,"totalTrials":228,"cells":2469},"Daclizumab",{"EARLY_PHASE1":2470,"PHASE1":2472,"PHASE2":2474,"PHASE3":2476,"PHASE4":2478,"NA":2490},{"trials":2471,"activeCount":98},[],{"trials":2473,"activeCount":98},[],{"trials":2475,"activeCount":98},[],{"trials":2477,"activeCount":98},[],{"trials":2479,"activeCount":98},[2480],{"nctId":2481,"briefTitle":2482,"status":136,"phases":2483,"primaryCompletion":2484,"completion":2484,"start":2485,"enrollment":2486,"conditions":2487,"interventions":2489},"NCT00363116","A Trial of Two Daclizumab Dosing Strategies vs. No Induction Treatment With Tacrolimus, Mycophenolate Mofetil , & Steroids for the Prevention of Acute Allograft Rejection in Simultaneous Kidney\u002FPancreas Transplant Recipients",[91],"2004-12","1999-04",298,[2488],"Acute Allograft Rejection in Simultaneous Kidney\u002FPancreas Transplant Recipients",[2468],{"trials":2491,"activeCount":98},[],{"intervention":2493,"totalTrials":228,"cells":2494},"Pirfenidone",{"EARLY_PHASE1":2495,"PHASE1":2497,"PHASE2":2499,"PHASE3":2501,"PHASE4":2503,"NA":2516},{"trials":2496,"activeCount":98},[],{"trials":2498,"activeCount":98},[],{"trials":2500,"activeCount":98},[],{"trials":2502,"activeCount":98},[],{"trials":2504,"activeCount":98},[2505],{"nctId":2506,"briefTitle":2507,"status":775,"phases":2508,"primaryCompletion":2509,"completion":2510,"start":2511,"enrollment":8,"conditions":2512,"interventions":2514},"NCT03260556","Pirfenidone for Progressive Fibrotic Sarcoidosis",[91],"2019-12-31","2020-03-30","2017-09-27",[2513],"Sarcoidosis, Pulmonary",[2493,2515],"Placebos",{"trials":2517,"activeCount":98},[],{"intervention":2515,"totalTrials":228,"cells":2519},{"EARLY_PHASE1":2520,"PHASE1":2522,"PHASE2":2524,"PHASE3":2526,"PHASE4":2528,"NA":2534},{"trials":2521,"activeCount":98},[],{"trials":2523,"activeCount":98},[],{"trials":2525,"activeCount":98},[],{"trials":2527,"activeCount":98},[],{"trials":2529,"activeCount":98},[2530],{"nctId":2506,"briefTitle":2507,"status":775,"phases":2531,"primaryCompletion":2509,"completion":2510,"start":2511,"enrollment":8,"conditions":2532,"interventions":2533},[91],[2513],[2493,2515],{"trials":2535,"activeCount":98},[],{"intervention":2537,"totalTrials":228,"cells":2538},"Levetiracetam",{"EARLY_PHASE1":2539,"PHASE1":2541,"PHASE2":2543,"PHASE3":2545,"PHASE4":2547,"NA":2558},{"trials":2540,"activeCount":98},[],{"trials":2542,"activeCount":98},[],{"trials":2544,"activeCount":98},[],{"trials":2546,"activeCount":98},[],{"trials":2548,"activeCount":98},[2549],{"nctId":2550,"briefTitle":2551,"status":136,"phases":2552,"primaryCompletion":2000,"completion":2000,"start":1637,"enrollment":2553,"conditions":2554,"interventions":2556},"NCT00618436","Assess Safety and Efficacy of Levetiracetam(LEV;Keppra)for Seizure Prevention",[91],52,[24,2555],"Subarachnoid Hemorrhage",[2537,2557],"Phenytoin",{"trials":2559,"activeCount":98},[],{"intervention":2557,"totalTrials":228,"cells":2561},{"EARLY_PHASE1":2562,"PHASE1":2564,"PHASE2":2566,"PHASE3":2568,"PHASE4":2570,"NA":2576},{"trials":2563,"activeCount":98},[],{"trials":2565,"activeCount":98},[],{"trials":2567,"activeCount":98},[],{"trials":2569,"activeCount":98},[],{"trials":2571,"activeCount":98},[2572],{"nctId":2550,"briefTitle":2551,"status":136,"phases":2573,"primaryCompletion":2000,"completion":2000,"start":1637,"enrollment":2553,"conditions":2574,"interventions":2575},[91],[24,2555],[2537,2557],{"trials":2577,"activeCount":98},[],{"intervention":955,"totalTrials":194,"cells":2579},{"EARLY_PHASE1":2580,"PHASE1":2582,"PHASE2":2584,"PHASE3":2590,"PHASE4":2596,"NA":2598},{"trials":2581,"activeCount":98},[],{"trials":2583,"activeCount":98},[],{"trials":2585,"activeCount":98},[2586],{"nctId":947,"briefTitle":948,"status":136,"phases":2587,"completion":950,"start":951,"enrollment":627,"conditions":2588,"interventions":2589},[89],[953],[955,956],{"trials":2591,"activeCount":98},[2592],{"nctId":972,"briefTitle":973,"status":136,"phases":2593,"completion":950,"start":975,"enrollment":976,"conditions":2594,"interventions":2595},[90],[978],[955,956],{"trials":2597,"activeCount":98},[],{"trials":2599,"activeCount":98},[],{"intervention":2601,"totalTrials":228,"cells":2602},"Rifaximin",{"EARLY_PHASE1":2603,"PHASE1":2605,"PHASE2":2607,"PHASE3":2609,"PHASE4":2619,"NA":2621},{"trials":2604,"activeCount":98},[],{"trials":2606,"activeCount":98},[],{"trials":2608,"activeCount":98},[],{"trials":2610,"activeCount":98},[2611],{"nctId":2612,"briefTitle":2613,"status":136,"phases":2614,"primaryCompletion":2615,"completion":2615,"start":140,"enrollment":154,"conditions":2616,"interventions":2618},"NCT02470780","Treating Bacterial Overgrowth in Parkinson's Disease",[89,90],"2017-08",[988,2617],"Small Intestinal Bacterial Overgrowth",[2601],{"trials":2620,"activeCount":98},[],{"trials":2622,"activeCount":98},[],{"intervention":2624,"totalTrials":228,"cells":2625},"Omega",{"EARLY_PHASE1":2626,"PHASE1":2628,"PHASE2":2630,"PHASE3":2632,"PHASE4":2642,"NA":2644},{"trials":2627,"activeCount":98},[],{"trials":2629,"activeCount":98},[],{"trials":2631,"activeCount":98},[],{"trials":2633,"activeCount":98},[2634],{"nctId":2635,"briefTitle":2636,"status":136,"phases":2637,"primaryCompletion":1813,"completion":1813,"start":2096,"enrollment":761,"conditions":2638,"interventions":2640},"NCT01858948","SGA-induced Metabolic Syndrome in Bipolar Youth",[90],[2639],"Bipolar Youth Treated With Second-generation Antipsychotics",[2624,2641],"Quetiapine fumarate",{"trials":2643,"activeCount":98},[],{"trials":2645,"activeCount":98},[],{"intervention":2641,"totalTrials":228,"cells":2647},{"EARLY_PHASE1":2648,"PHASE1":2650,"PHASE2":2652,"PHASE3":2654,"PHASE4":2660,"NA":2662},{"trials":2649,"activeCount":98},[],{"trials":2651,"activeCount":98},[],{"trials":2653,"activeCount":98},[],{"trials":2655,"activeCount":98},[2656],{"nctId":2635,"briefTitle":2636,"status":136,"phases":2657,"primaryCompletion":1813,"completion":1813,"start":2096,"enrollment":761,"conditions":2658,"interventions":2659},[90],[2639],[2624,2641],{"trials":2661,"activeCount":98},[],{"trials":2663,"activeCount":98},[],{"intervention":1201,"totalTrials":228,"cells":2665},{"EARLY_PHASE1":2666,"PHASE1":2668,"PHASE2":2670,"PHASE3":2672,"PHASE4":2678,"NA":2680},{"trials":2667,"activeCount":98},[],{"trials":2669,"activeCount":98},[],{"trials":2671,"activeCount":98},[],{"trials":2673,"activeCount":98},[2674],{"nctId":1191,"briefTitle":1192,"status":775,"phases":2675,"primaryCompletion":1194,"completion":1195,"start":1196,"enrollment":8,"conditions":2676,"interventions":2677},[89,90],[27,1198,1199],[1180,1201],{"trials":2679,"activeCount":98},[],{"trials":2681,"activeCount":98},[],{"intervention":2683,"totalTrials":228,"cells":2684},"Osmotic-Release Methylphenidate",{"EARLY_PHASE1":2685,"PHASE1":2687,"PHASE2":2689,"PHASE3":2691,"PHASE4":2703,"NA":2705},{"trials":2686,"activeCount":98},[],{"trials":2688,"activeCount":98},[],{"trials":2690,"activeCount":98},[],{"trials":2692,"activeCount":98},[2693],{"nctId":2694,"briefTitle":2695,"status":136,"phases":2696,"primaryCompletion":928,"completion":2697,"start":2698,"enrollment":2699,"conditions":2700,"interventions":2702},"NCT00253747","Smoking Cessation for Adults With Attention Deficit Hyperactivity Disorder (ADHD)",[90],"2008-03","2005-11",255,[967,2701],"Smoking",[2683],{"trials":2704,"activeCount":98},[],{"trials":2706,"activeCount":98},[],{"intervention":2708,"totalTrials":228,"cells":2709},"Armodafinil",{"EARLY_PHASE1":2710,"PHASE1":2712,"PHASE2":2714,"PHASE3":2716,"PHASE4":2728,"NA":2730},{"trials":2711,"activeCount":98},[],{"trials":2713,"activeCount":98},[],{"trials":2715,"activeCount":98},[],{"trials":2717,"activeCount":98},[2718],{"nctId":2719,"briefTitle":2720,"status":136,"phases":2721,"primaryCompletion":506,"completion":2722,"start":2723,"enrollment":328,"conditions":2724,"interventions":2727},"NCT00555347","Use of Armodafinil for Fatigue in Sarcoidosis",[89,90],"2011-08","2007-10",[18,2725,2726],"Fatigue","Sleepiness",[2708],{"trials":2729,"activeCount":98},[],{"trials":2731,"activeCount":98},[],{"intervention":970,"totalTrials":228,"cells":2733},{"EARLY_PHASE1":2734,"PHASE1":2736,"PHASE2":2738,"PHASE3":2740,"PHASE4":2746,"NA":2748},{"trials":2735,"activeCount":98},[],{"trials":2737,"activeCount":98},[],{"trials":2739,"activeCount":98},[],{"trials":2741,"activeCount":98},[2742],{"nctId":960,"briefTitle":961,"status":136,"phases":2743,"primaryCompletion":963,"completion":963,"start":964,"enrollment":965,"conditions":2744,"interventions":2745},[90],[967,968],[938,970],{"trials":2747,"activeCount":98},[],{"trials":2749,"activeCount":98},[],{"intervention":2751,"totalTrials":228,"cells":2752},"CC-100004",{"EARLY_PHASE1":2753,"PHASE1":2755,"PHASE2":2757,"PHASE3":2759,"PHASE4":2768,"NA":2770},{"trials":2754,"activeCount":98},[],{"trials":2756,"activeCount":98},[],{"trials":2758,"activeCount":98},[],{"trials":2760,"activeCount":98},[2761],{"nctId":2762,"briefTitle":2763,"status":136,"phases":2764,"primaryCompletion":1287,"completion":1287,"start":1490,"enrollment":2049,"conditions":2765,"interventions":2767},"NCT00794274","The Efficacy and Safety of CC-10004 in Chronic Cutaneous Sarcoidosis",[89,90],[18,2766],"Cutaneous Sarcoidosis",[2751],{"trials":2769,"activeCount":98},[],{"trials":2771,"activeCount":98},[],{"intervention":2773,"totalTrials":228,"cells":2774},"Aripiprazole",{"EARLY_PHASE1":2775,"PHASE1":2777,"PHASE2":2779,"PHASE3":2781,"PHASE4":2790,"NA":2792},{"trials":2776,"activeCount":98},[],{"trials":2778,"activeCount":98},[],{"trials":2780,"activeCount":98},[],{"trials":2782,"activeCount":98},[2783],{"nctId":2784,"briefTitle":2785,"status":136,"phases":2786,"primaryCompletion":963,"completion":1397,"start":2787,"enrollment":627,"conditions":2788,"interventions":2789},"NCT00221416","An Open-Label Trial of Aripiprazole in Children and Adolescents With Bipolar Disorder",[90],"2005-06",[21],[2773],{"trials":2791,"activeCount":98},[],{"trials":2793,"activeCount":98},[],{"intervention":2795,"totalTrials":228,"cells":2796},"Low Dose Fish Oil",{"EARLY_PHASE1":2797,"PHASE1":2799,"PHASE2":2801,"PHASE3":2803,"PHASE4":2813,"NA":2815},{"trials":2798,"activeCount":98},[],{"trials":2800,"activeCount":98},[],{"trials":2802,"activeCount":98},[],{"trials":2804,"activeCount":98},[2805],{"nctId":2806,"briefTitle":2807,"status":136,"phases":2808,"primaryCompletion":2809,"completion":2809,"start":1637,"enrollment":328,"conditions":2810,"interventions":2811},"NCT00511810","Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder",[89,90],"2011-03",[1211],[2795,2812],"High Dose Fish Oil",{"trials":2814,"activeCount":98},[],{"trials":2816,"activeCount":98},[],{"intervention":2812,"totalTrials":228,"cells":2818},{"EARLY_PHASE1":2819,"PHASE1":2821,"PHASE2":2823,"PHASE3":2825,"PHASE4":2831,"NA":2833},{"trials":2820,"activeCount":98},[],{"trials":2822,"activeCount":98},[],{"trials":2824,"activeCount":98},[],{"trials":2826,"activeCount":98},[2827],{"nctId":2806,"briefTitle":2807,"status":136,"phases":2828,"primaryCompletion":2809,"completion":2809,"start":1637,"enrollment":328,"conditions":2829,"interventions":2830},[89,90],[1211],[2795,2812],{"trials":2832,"activeCount":98},[],{"trials":2834,"activeCount":98},[],{"intervention":2836,"totalTrials":228,"cells":2837},"Mannitol",{"EARLY_PHASE1":2838,"PHASE1":2840,"PHASE2":2842,"PHASE3":2844,"PHASE4":2856,"NA":2858},{"trials":2839,"activeCount":98},[],{"trials":2841,"activeCount":98},[],{"trials":2843,"activeCount":98},[],{"trials":2845,"activeCount":98},[2846],{"nctId":2847,"briefTitle":2848,"status":756,"phases":2849,"primaryCompletion":2850,"completion":2850,"start":2851,"enrollment":34,"conditions":2852,"interventions":2854},"NCT01111682","Hypertonic Saline vs. Mannitol for Elevated Intercranial Pressure",[90],"2010-11","2010-04",[24,2853],"Elevated Intracranial Pressure",[2836,2855],"Hypertonic Saline",{"trials":2857,"activeCount":98},[],{"trials":2859,"activeCount":98},[],{"intervention":2855,"totalTrials":228,"cells":2861},{"EARLY_PHASE1":2862,"PHASE1":2864,"PHASE2":2866,"PHASE3":2868,"PHASE4":2874,"NA":2876},{"trials":2863,"activeCount":98},[],{"trials":2865,"activeCount":98},[],{"trials":2867,"activeCount":98},[],{"trials":2869,"activeCount":98},[2870],{"nctId":2847,"briefTitle":2848,"status":756,"phases":2871,"primaryCompletion":2850,"completion":2850,"start":2851,"enrollment":34,"conditions":2872,"interventions":2873},[90],[24,2853],[2836,2855],{"trials":2875,"activeCount":98},[],{"trials":2877,"activeCount":98},[],{"intervention":2879,"totalTrials":228,"cells":2880},"Inhaled Nitric Oxide",{"EARLY_PHASE1":2881,"PHASE1":2883,"PHASE2":2885,"PHASE3":2887,"PHASE4":2897,"NA":2899},{"trials":2882,"activeCount":98},[],{"trials":2884,"activeCount":98},[],{"trials":2886,"activeCount":98},[],{"trials":2888,"activeCount":98},[2889],{"nctId":2890,"briefTitle":2891,"status":136,"phases":2892,"primaryCompletion":2893,"completion":2893,"start":2894,"enrollment":19,"conditions":2895,"interventions":2896},"NCT03260569","Inhaled Nitric Oxide in Brain Injury",[90],"2023-12-28","2018-12-12",[24],[2879],{"trials":2898,"activeCount":98},[],{"trials":2900,"activeCount":98},[],{"intervention":2902,"totalTrials":228,"cells":2903},"Atomoxetine",{"EARLY_PHASE1":2904,"PHASE1":2906,"PHASE2":2908,"PHASE3":2910,"PHASE4":2919,"NA":2921},{"trials":2905,"activeCount":98},[],{"trials":2907,"activeCount":98},[],{"trials":2909,"activeCount":98},[],{"trials":2911,"activeCount":98},[2912],{"nctId":2913,"briefTitle":2914,"status":775,"phases":2915,"primaryCompletion":2073,"completion":2073,"start":2000,"enrollment":780,"conditions":2916,"interventions":2917},"NCT01330693","Cortical Excitability: Phenotype and Biomarker in Attention-deficit, Hyperactivity Disorder (ADHD) Therapy",[90],[978],[2902,2918],"Sugar Pill",{"trials":2920,"activeCount":98},[],{"trials":2922,"activeCount":98},[],{"intervention":2918,"totalTrials":228,"cells":2924},{"EARLY_PHASE1":2925,"PHASE1":2927,"PHASE2":2929,"PHASE3":2931,"PHASE4":2937,"NA":2939},{"trials":2926,"activeCount":98},[],{"trials":2928,"activeCount":98},[],{"trials":2930,"activeCount":98},[],{"trials":2932,"activeCount":98},[2933],{"nctId":2913,"briefTitle":2914,"status":775,"phases":2934,"primaryCompletion":2073,"completion":2073,"start":2000,"enrollment":780,"conditions":2935,"interventions":2936},[90],[978],[2902,2918],{"trials":2938,"activeCount":98},[],{"trials":2940,"activeCount":98},[],{"intervention":2942,"totalTrials":228,"cells":2943},"Bosentan",{"EARLY_PHASE1":2944,"PHASE1":2946,"PHASE2":2948,"PHASE3":2950,"PHASE4":2960,"NA":2962},{"trials":2945,"activeCount":98},[],{"trials":2947,"activeCount":98},[],{"trials":2949,"activeCount":98},[],{"trials":2951,"activeCount":98},[2952],{"nctId":2953,"briefTitle":2954,"status":136,"phases":2955,"primaryCompletion":2956,"completion":1006,"start":1277,"enrollment":2957,"conditions":2958,"interventions":2959},"NCT00581607","Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension",[89,90],"2012-10",43,[18,1839],[2942,2942],{"trials":2961,"activeCount":98},[],{"trials":2963,"activeCount":98},[],{"intervention":2965,"totalTrials":228,"cells":2966},"Ketamine",{"EARLY_PHASE1":2967,"PHASE1":2969,"PHASE2":2971,"PHASE3":2973,"PHASE4":2986,"NA":2988},{"trials":2968,"activeCount":98},[],{"trials":2970,"activeCount":98},[],{"trials":2972,"activeCount":98},[],{"trials":2974,"activeCount":98},[2975],{"nctId":2976,"briefTitle":2977,"status":756,"phases":2978,"primaryCompletion":2979,"completion":2979,"start":1172,"enrollment":328,"conditions":2980,"interventions":2984},"NCT02062879","Ketamine Patient-Controlled Analgesia for Acute Pain",[90],"2016-06",[2981,2982,2983],"Acute Pain","Multiple Trauma","Fractures",[2965,2985],"Hydromorphone",{"trials":2987,"activeCount":98},[],{"trials":2989,"activeCount":98},[],{"intervention":2985,"totalTrials":228,"cells":2991},{"EARLY_PHASE1":2992,"PHASE1":2994,"PHASE2":2996,"PHASE3":2998,"PHASE4":3004,"NA":3006},{"trials":2993,"activeCount":98},[],{"trials":2995,"activeCount":98},[],{"trials":2997,"activeCount":98},[],{"trials":2999,"activeCount":98},[3000],{"nctId":2976,"briefTitle":2977,"status":756,"phases":3001,"primaryCompletion":2979,"completion":2979,"start":1172,"enrollment":328,"conditions":3002,"interventions":3003},[90],[2981,2982,2983],[2965,2985],{"trials":3005,"activeCount":98},[],{"trials":3007,"activeCount":98},[],{"intervention":3009,"totalTrials":228,"cells":3010},"DHA Omega-3",{"EARLY_PHASE1":3011,"PHASE1":3013,"PHASE2":3015,"PHASE3":3017,"PHASE4":3028,"NA":3030},{"trials":3012,"activeCount":98},[],{"trials":3014,"activeCount":98},[],{"trials":3016,"activeCount":98},[],{"trials":3018,"activeCount":98},[3019],{"nctId":3020,"briefTitle":3021,"status":136,"phases":3022,"primaryCompletion":3023,"completion":3023,"start":3024,"enrollment":627,"conditions":3025,"interventions":3027},"NCT01883817","Effect of Omega-3 Fatty Acid on Cortical Function in ADHD",[90],"2017-03-03","2013-09",[3026],"Attention Deficit Disorder",[3009],{"trials":3029,"activeCount":98},[],{"trials":3031,"activeCount":98},[],{"intervention":3033,"totalTrials":228,"cells":3034},"Fluoxetine",{"EARLY_PHASE1":3035,"PHASE1":3037,"PHASE2":3039,"PHASE3":3041,"PHASE4":3051,"NA":3053},{"trials":3036,"activeCount":98},[],{"trials":3038,"activeCount":98},[],{"trials":3040,"activeCount":98},[],{"trials":3042,"activeCount":98},[3043],{"nctId":3044,"briefTitle":3045,"status":136,"phases":3046,"primaryCompletion":315,"completion":315,"start":2787,"enrollment":31,"conditions":3047,"interventions":3050},"NCT00115804","Safety and Efficacy of Fluoxetine in Juvenile Fibromyalgia",[90],[3048,3049],"Juvenile Primary Fibromyalgia Syndrome (JPFS)","Fibromyalgia",[3033],{"trials":3052,"activeCount":98},[],{"trials":3054,"activeCount":98},[],{"intervention":3056,"totalTrials":228,"cells":3057},"Dexmedetomidine",{"EARLY_PHASE1":3058,"PHASE1":3060,"PHASE2":3062,"PHASE3":3064,"PHASE4":3075,"NA":3077},{"trials":3059,"activeCount":98},[],{"trials":3061,"activeCount":98},[],{"trials":3063,"activeCount":98},[],{"trials":3065,"activeCount":98},[3066],{"nctId":3067,"briefTitle":3068,"status":756,"phases":3069,"primaryCompletion":1396,"completion":1396,"start":3070,"enrollment":154,"conditions":3071,"interventions":3073},"NCT01565590","Effects of Dexmedetomidine on Inflammatory Cytokines in Patients With Aneurysmal Subarachnoid Hemorrhage",[90],"2012-02",[3072],"Subarachnoid Hemorrhage, Aneurysmal",[3056,3074],"propofol",{"trials":3076,"activeCount":98},[],{"trials":3078,"activeCount":98},[],{"intervention":3074,"totalTrials":228,"cells":3080},{"EARLY_PHASE1":3081,"PHASE1":3083,"PHASE2":3085,"PHASE3":3087,"PHASE4":3093,"NA":3095},{"trials":3082,"activeCount":98},[],{"trials":3084,"activeCount":98},[],{"trials":3086,"activeCount":98},[],{"trials":3088,"activeCount":98},[3089],{"nctId":3067,"briefTitle":3068,"status":756,"phases":3090,"primaryCompletion":1396,"completion":1396,"start":3070,"enrollment":154,"conditions":3091,"interventions":3092},[90],[3072],[3056,3074],{"trials":3094,"activeCount":98},[],{"trials":3096,"activeCount":98},[],{"intervention":512,"totalTrials":194,"cells":3098},{"EARLY_PHASE1":3099,"PHASE1":3101,"PHASE2":3103,"PHASE3":3118,"PHASE4":3120,"NA":3122},{"trials":3100,"activeCount":98},[],{"trials":3102,"activeCount":98},[],{"trials":3104,"activeCount":98},[3105,3114],{"nctId":3106,"briefTitle":3107,"status":503,"phases":3108,"primaryCompletion":3109,"completion":3109,"start":3110,"enrollment":98,"conditions":3111,"interventions":3113},"NCT00570375","The Role of Erlotinib an Epidermal Growth Factor Receptor (EGFR) Inhibitor in the Treatment of Myelodysplastic Syndrome",[89],"2009-04","2007-11",[3112],"Myelodysplastic Syndrome",[512],{"nctId":501,"briefTitle":502,"status":503,"phases":3115,"primaryCompletion":505,"completion":506,"start":507,"enrollment":98,"conditions":3116,"interventions":3117},[89],[509],[479,511,512],{"trials":3119,"activeCount":98},[],{"trials":3121,"activeCount":98},[],{"trials":3123,"activeCount":98},[],{"intervention":3125,"totalTrials":228,"cells":3126},"recombinant activated factor VII",{"EARLY_PHASE1":3127,"PHASE1":3129,"PHASE2":3131,"PHASE3":3142,"PHASE4":3144,"NA":3146},{"trials":3128,"activeCount":98},[],{"trials":3130,"activeCount":98},[],{"trials":3132,"activeCount":98},[3133],{"nctId":3134,"briefTitle":3135,"status":136,"phases":3136,"primaryCompletion":3137,"completion":3137,"start":2850,"enrollment":3138,"conditions":3139,"interventions":3141},"NCT00810888","The Spot Sign for Predicting and Treating ICH Growth Study",[89],"2016-04",92,[3140],"Intracerebral Hemorrhage",[3125],{"trials":3143,"activeCount":98},[],{"trials":3145,"activeCount":98},[],{"trials":3147,"activeCount":98},[],{"intervention":3149,"totalTrials":228,"cells":3150},"Buspirone",{"EARLY_PHASE1":3151,"PHASE1":3153,"PHASE2":3155,"PHASE3":3166,"PHASE4":3168,"NA":3170},{"trials":3152,"activeCount":98},[],{"trials":3154,"activeCount":98},[],{"trials":3156,"activeCount":98},[3157],{"nctId":3158,"briefTitle":3159,"status":136,"phases":3160,"primaryCompletion":1112,"completion":1112,"start":3161,"enrollment":3162,"conditions":3163,"interventions":3165},"NCT01641159","Study of Buspirone for Relapse-Prevention in Adults With Cocaine Dependence",[89],"2012-08",62,[3164],"Cocaine Dependence",[3149],{"trials":3167,"activeCount":98},[],{"trials":3169,"activeCount":98},[],{"trials":3171,"activeCount":98},[],{"intervention":3173,"totalTrials":228,"cells":3174},"SB-728-T",{"EARLY_PHASE1":3175,"PHASE1":3177,"PHASE2":3179,"PHASE3":3191,"PHASE4":3193,"NA":3195},{"trials":3176,"activeCount":98},[],{"trials":3178,"activeCount":98},[],{"trials":3180,"activeCount":98},[3181],{"nctId":3182,"briefTitle":3183,"status":136,"phases":3184,"primaryCompletion":3185,"completion":3186,"start":3187,"enrollment":627,"conditions":3188,"interventions":3189},"NCT03666871","CCR5-modified CD4+ T Cells for HIV Infection",[88,89],"2024-01-31","2024-02-28","2019-06-12",[2144],[3173,3190],"Expanded unmodified autologous CD4+ T cells",{"trials":3192,"activeCount":98},[],{"trials":3194,"activeCount":98},[],{"trials":3196,"activeCount":98},[],{"intervention":3190,"totalTrials":228,"cells":3198},{"EARLY_PHASE1":3199,"PHASE1":3201,"PHASE2":3203,"PHASE3":3209,"PHASE4":3211,"NA":3213},{"trials":3200,"activeCount":98},[],{"trials":3202,"activeCount":98},[],{"trials":3204,"activeCount":98},[3205],{"nctId":3182,"briefTitle":3183,"status":136,"phases":3206,"primaryCompletion":3185,"completion":3186,"start":3187,"enrollment":627,"conditions":3207,"interventions":3208},[88,89],[2144],[3173,3190],{"trials":3210,"activeCount":98},[],{"trials":3212,"activeCount":98},[],{"trials":3214,"activeCount":98},[],{"intervention":3216,"totalTrials":228,"cells":3217},"Budesonide 3Mg",{"EARLY_PHASE1":3218,"PHASE1":3220,"PHASE2":3222,"PHASE3":3234,"PHASE4":3236,"NA":3238},{"trials":3219,"activeCount":98},[],{"trials":3221,"activeCount":98},[],{"trials":3223,"activeCount":98},[3224],{"nctId":3225,"briefTitle":3226,"status":136,"phases":3227,"primaryCompletion":2509,"completion":2509,"start":3228,"enrollment":182,"conditions":3229,"interventions":3232},"NCT03304626","Budesonide for Liver Transplant Immune Suppression",[89],"2017-06-27",[3230,3231],"Acute Cellular Graft Rejection","New Onset Diabetes After Transplant",[3216,3233],"Standard of Care Prednisone",{"trials":3235,"activeCount":98},[],{"trials":3237,"activeCount":98},[],{"trials":3239,"activeCount":98},[],{"intervention":3233,"totalTrials":228,"cells":3241},{"EARLY_PHASE1":3242,"PHASE1":3244,"PHASE2":3246,"PHASE3":3252,"PHASE4":3254,"NA":3256},{"trials":3243,"activeCount":98},[],{"trials":3245,"activeCount":98},[],{"trials":3247,"activeCount":98},[3248],{"nctId":3225,"briefTitle":3226,"status":136,"phases":3249,"primaryCompletion":2509,"completion":2509,"start":3228,"enrollment":182,"conditions":3250,"interventions":3251},[89],[3230,3231],[3216,3233],{"trials":3253,"activeCount":98},[],{"trials":3255,"activeCount":98},[],{"trials":3257,"activeCount":98},[],{"intervention":3259,"totalTrials":228,"cells":3260},"Citalopram + MI",{"EARLY_PHASE1":3261,"PHASE1":3263,"PHASE2":3265,"PHASE3":3277,"PHASE4":3279,"NA":3281},{"trials":3262,"activeCount":98},[],{"trials":3264,"activeCount":98},[],{"trials":3266,"activeCount":98},[3267],{"nctId":3268,"briefTitle":3269,"status":136,"phases":3270,"primaryCompletion":3271,"completion":3271,"start":3272,"enrollment":3273,"conditions":3274,"interventions":3276},"NCT00249405","Predicting Alcoholics' Treatment Responses to a Selective Serotonin Re-uptake Inhibitor (SSRI)",[89],"2010-10","2005-02",200,[3275,1280],"Alcoholism",[3259],{"trials":3278,"activeCount":98},[],{"trials":3280,"activeCount":98},[],{"trials":3282,"activeCount":98},[],{"intervention":3284,"totalTrials":228,"cells":3285},"Imatinib Mesylate",{"EARLY_PHASE1":3286,"PHASE1":3288,"PHASE2":3290,"PHASE3":3301,"PHASE4":3303,"NA":3305},{"trials":3287,"activeCount":98},[],{"trials":3289,"activeCount":98},[],{"trials":3291,"activeCount":98},[3292],{"nctId":3293,"briefTitle":3294,"status":503,"phases":3295,"primaryCompletion":1490,"completion":1490,"start":3110,"enrollment":328,"conditions":3296,"interventions":3299},"NCT00594555","A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia",[89],[3297,3298],"Chronic Myeloid Leukemia, Blast Crisis","Acute Myeloid Leukemia",[3284,3300],"CLAG",{"trials":3302,"activeCount":98},[],{"trials":3304,"activeCount":98},[],{"trials":3306,"activeCount":98},[],{"intervention":3300,"totalTrials":228,"cells":3308},{"EARLY_PHASE1":3309,"PHASE1":3311,"PHASE2":3313,"PHASE3":3319,"PHASE4":3321,"NA":3323},{"trials":3310,"activeCount":98},[],{"trials":3312,"activeCount":98},[],{"trials":3314,"activeCount":98},[3315],{"nctId":3293,"briefTitle":3294,"status":503,"phases":3316,"primaryCompletion":1490,"completion":1490,"start":3110,"enrollment":328,"conditions":3317,"interventions":3318},[89],[3297,3298],[3284,3300],{"trials":3320,"activeCount":98},[],{"trials":3322,"activeCount":98},[],{"trials":3324,"activeCount":98},[],{"intervention":3326,"totalTrials":228,"cells":3327},"Asenapine",{"EARLY_PHASE1":3328,"PHASE1":3330,"PHASE2":3332,"PHASE3":3343,"PHASE4":3345,"NA":3347},{"trials":3329,"activeCount":98},[],{"trials":3331,"activeCount":98},[],{"trials":3333,"activeCount":98},[3334],{"nctId":3335,"briefTitle":3336,"status":756,"phases":3337,"primaryCompletion":3338,"completion":3338,"start":3024,"enrollment":3339,"conditions":3340,"interventions":3342},"NCT01807741","Asenapine for Bipolar Depression",[89],"2017-07",51,[3341],"Bipolar Depression",[3326],{"trials":3344,"activeCount":98},[],{"trials":3346,"activeCount":98},[],{"trials":3348,"activeCount":98},[],{"intervention":3350,"totalTrials":228,"cells":3351},"Probenecid 1 gr oral twice daily",{"EARLY_PHASE1":3352,"PHASE1":3354,"PHASE2":3356,"PHASE3":3366,"PHASE4":3368,"NA":3370},{"trials":3353,"activeCount":98},[],{"trials":3355,"activeCount":98},[],{"trials":3357,"activeCount":98},[3358],{"nctId":3359,"briefTitle":3360,"status":136,"phases":3361,"primaryCompletion":3362,"completion":3362,"start":1007,"enrollment":328,"conditions":3363,"interventions":3365},"NCT01814319","Repurposing Probenecid as a Positive Inotrope for the Treatment of Heart Failure",[89],"2015-06",[3364],"Systolic Heart Failure",[3350],{"trials":3367,"activeCount":98},[],{"trials":3369,"activeCount":98},[],{"trials":3371,"activeCount":98},[],{"intervention":290,"totalTrials":228,"cells":3373},{"EARLY_PHASE1":3374,"PHASE1":3376,"PHASE2":3378,"PHASE3":3384,"PHASE4":3386,"NA":3388},{"trials":3375,"activeCount":98},[],{"trials":3377,"activeCount":98},[],{"trials":3379,"activeCount":98},[3380],{"nctId":283,"briefTitle":284,"status":136,"phases":3381,"primaryCompletion":286,"completion":286,"start":287,"enrollment":11,"conditions":3382,"interventions":3383},[89],[33],[52,290],{"trials":3385,"activeCount":98},[],{"trials":3387,"activeCount":98},[],{"trials":3389,"activeCount":98},[],{"intervention":3391,"totalTrials":228,"cells":3392},"Trental",{"EARLY_PHASE1":3393,"PHASE1":3395,"PHASE2":3397,"PHASE3":3408,"PHASE4":3410,"NA":3412},{"trials":3394,"activeCount":98},[],{"trials":3396,"activeCount":98},[],{"trials":3398,"activeCount":98},[3399],{"nctId":3400,"briefTitle":3401,"status":136,"phases":3402,"primaryCompletion":3403,"completion":3403,"start":3404,"enrollment":2001,"conditions":3405,"interventions":3407},"NCT01508221","Evaluation of the Use of Trental and Vitamin E For Prophylaxis of Radiation Necrosis",[89],"2017-02-01","2011-06",[3406],"Brain Metastasis",[3391],{"trials":3409,"activeCount":98},[],{"trials":3411,"activeCount":98},[],{"trials":3413,"activeCount":98},[],{"intervention":3415,"totalTrials":228,"cells":3416},"Durvalumab",{"EARLY_PHASE1":3417,"PHASE1":3419,"PHASE2":3421,"PHASE3":3435,"PHASE4":3437,"NA":3439},{"trials":3418,"activeCount":98},[],{"trials":3420,"activeCount":98},[],{"trials":3422,"activeCount":98},[3423],{"nctId":3424,"briefTitle":3425,"status":756,"phases":3426,"primaryCompletion":3427,"completion":3427,"start":3428,"enrollment":25,"conditions":3429,"interventions":3433},"NCT05027425","Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant",[89],"2024-11-07","2021-12-07",[3430,3431,3432],"Hepatocellular Carcinoma","Cirrhosis","Portal Hypertension",[3415,3434],"Tremelimumab",{"trials":3436,"activeCount":98},[],{"trials":3438,"activeCount":98},[],{"trials":3440,"activeCount":98},[],{"intervention":3434,"totalTrials":228,"cells":3442},{"EARLY_PHASE1":3443,"PHASE1":3445,"PHASE2":3447,"PHASE3":3453,"PHASE4":3455,"NA":3457},{"trials":3444,"activeCount":98},[],{"trials":3446,"activeCount":98},[],{"trials":3448,"activeCount":98},[3449],{"nctId":3424,"briefTitle":3425,"status":756,"phases":3450,"primaryCompletion":3427,"completion":3427,"start":3428,"enrollment":25,"conditions":3451,"interventions":3452},[89],[3430,3431,3432],[3415,3434],{"trials":3454,"activeCount":98},[],{"trials":3456,"activeCount":98},[],{"trials":3458,"activeCount":98},[],{"intervention":3460,"totalTrials":228,"cells":3461},"Eptifibatide",{"EARLY_PHASE1":3462,"PHASE1":3464,"PHASE2":3466,"PHASE3":3478,"PHASE4":3480,"NA":3482},{"trials":3463,"activeCount":98},[],{"trials":3465,"activeCount":98},[],{"trials":3467,"activeCount":98},[3468],{"nctId":3469,"briefTitle":3470,"status":136,"phases":3471,"primaryCompletion":2956,"completion":1006,"start":1053,"enrollment":3472,"conditions":3473,"interventions":3476},"NCT00894803","Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke",[89],126,[3474,15,3475],"Ischemic Stroke","Brain Infarction",[3460,3477],"rt-PA",{"trials":3479,"activeCount":98},[],{"trials":3481,"activeCount":98},[],{"trials":3483,"activeCount":98},[],{"intervention":3477,"totalTrials":228,"cells":3485},{"EARLY_PHASE1":3486,"PHASE1":3488,"PHASE2":3490,"PHASE3":3496,"PHASE4":3498,"NA":3500},{"trials":3487,"activeCount":98},[],{"trials":3489,"activeCount":98},[],{"trials":3491,"activeCount":98},[3492],{"nctId":3469,"briefTitle":3470,"status":136,"phases":3493,"primaryCompletion":2956,"completion":1006,"start":1053,"enrollment":3472,"conditions":3494,"interventions":3495},[89],[3474,15,3475],[3460,3477],{"trials":3497,"activeCount":98},[],{"trials":3499,"activeCount":98},[],{"trials":3501,"activeCount":98},[],{"intervention":1014,"totalTrials":228,"cells":3503},{"EARLY_PHASE1":3504,"PHASE1":3506,"PHASE2":3508,"PHASE3":3514,"PHASE4":3516,"NA":3518},{"trials":3505,"activeCount":98},[],{"trials":3507,"activeCount":98},[],{"trials":3509,"activeCount":98},[3510],{"nctId":1003,"briefTitle":1004,"status":136,"phases":3511,"primaryCompletion":1006,"completion":1007,"start":1008,"enrollment":627,"conditions":3512,"interventions":3513},[89],[1010],[994,1012,1013,1014,1015,1016],{"trials":3515,"activeCount":98},[],{"trials":3517,"activeCount":98},[],{"trials":3519,"activeCount":98},[],{"intervention":3521,"totalTrials":228,"cells":3522},"OMega 3",{"EARLY_PHASE1":3523,"PHASE1":3525,"PHASE2":3527,"PHASE3":3537,"PHASE4":3539,"NA":3541},{"trials":3524,"activeCount":98},[],{"trials":3526,"activeCount":98},[],{"trials":3528,"activeCount":98},[3529],{"nctId":3530,"briefTitle":3531,"status":136,"phases":3532,"primaryCompletion":2096,"completion":2096,"start":807,"enrollment":3533,"conditions":3534,"interventions":3536},"NCT00917501","Neurochemical Effects of Omega-3 Fatty Acids in Adolescents at Risk for Mania",[89],55,[3535],"Mania",[3521],{"trials":3538,"activeCount":98},[],{"trials":3540,"activeCount":98},[],{"trials":3542,"activeCount":98},[],{"intervention":3544,"totalTrials":228,"cells":3545},"darunavir, ritonavir, rosuvastatin",{"EARLY_PHASE1":3546,"PHASE1":3548,"PHASE2":3550,"PHASE3":3559,"PHASE4":3561,"NA":3563},{"trials":3547,"activeCount":98},[],{"trials":3549,"activeCount":98},[],{"trials":3551,"activeCount":98},[3552],{"nctId":3553,"briefTitle":3554,"status":136,"phases":3555,"primaryCompletion":2851,"completion":506,"start":1636,"enrollment":340,"conditions":3556,"interventions":3557},"NCT00885495","Darunavir\u002FRitonavir and Rosuvastatin Pharmacokinetic Study",[88,89],[2144],[3544,3558],"rosuvastatin, darunavir, ritonavir",{"trials":3560,"activeCount":98},[],{"trials":3562,"activeCount":98},[],{"trials":3564,"activeCount":98},[],{"intervention":3558,"totalTrials":228,"cells":3566},{"EARLY_PHASE1":3567,"PHASE1":3569,"PHASE2":3571,"PHASE3":3577,"PHASE4":3579,"NA":3581},{"trials":3568,"activeCount":98},[],{"trials":3570,"activeCount":98},[],{"trials":3572,"activeCount":98},[3573],{"nctId":3553,"briefTitle":3554,"status":136,"phases":3574,"primaryCompletion":2851,"completion":506,"start":1636,"enrollment":340,"conditions":3575,"interventions":3576},[88,89],[2144],[3544,3558],{"trials":3578,"activeCount":98},[],{"trials":3580,"activeCount":98},[],{"trials":3582,"activeCount":98},[],{"intervention":3584,"totalTrials":228,"cells":3585},"Amifostine",{"EARLY_PHASE1":3586,"PHASE1":3588,"PHASE2":3590,"PHASE3":3600,"PHASE4":3602,"NA":3604},{"trials":3587,"activeCount":98},[],{"trials":3589,"activeCount":98},[],{"trials":3591,"activeCount":98},[3592],{"nctId":3593,"briefTitle":3594,"status":756,"phases":3595,"primaryCompletion":3596,"completion":3596,"start":181,"enrollment":154,"conditions":3597,"interventions":3599},"NCT00601198","A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer",[89],"2010-01-13",[3598],"Colorectal Cancer",[3584],{"trials":3601,"activeCount":98},[],{"trials":3603,"activeCount":98},[],{"trials":3605,"activeCount":98},[],{"intervention":3607,"totalTrials":228,"cells":3608},"Cetuximab",{"EARLY_PHASE1":3609,"PHASE1":3611,"PHASE2":3613,"PHASE3":3623,"PHASE4":3625,"NA":3627},{"trials":3610,"activeCount":98},[],{"trials":3612,"activeCount":98},[],{"trials":3614,"activeCount":98},[3615],{"nctId":3616,"briefTitle":3617,"status":136,"phases":3618,"primaryCompletion":3619,"completion":3619,"start":3620,"enrollment":393,"conditions":3621,"interventions":3622},"NCT01979211","Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck",[89],"2022-01-19","2013-10",[461],[3607],{"trials":3624,"activeCount":98},[],{"trials":3626,"activeCount":98},[],{"trials":3628,"activeCount":98},[],{"intervention":811,"totalTrials":228,"cells":3630},{"EARLY_PHASE1":3631,"PHASE1":3633,"PHASE2":3635,"PHASE3":3641,"PHASE4":3643,"NA":3645},{"trials":3632,"activeCount":98},[],{"trials":3634,"activeCount":98},[],{"trials":3636,"activeCount":98},[3637],{"nctId":803,"briefTitle":804,"status":503,"phases":3638,"primaryCompletion":806,"completion":806,"start":807,"enrollment":98,"conditions":3639,"interventions":3640},[88,89],[809],[811,812,794],{"trials":3642,"activeCount":98},[],{"trials":3644,"activeCount":98},[],{"trials":3646,"activeCount":98},[],{"intervention":812,"totalTrials":228,"cells":3648},{"EARLY_PHASE1":3649,"PHASE1":3651,"PHASE2":3653,"PHASE3":3659,"PHASE4":3661,"NA":3663},{"trials":3650,"activeCount":98},[],{"trials":3652,"activeCount":98},[],{"trials":3654,"activeCount":98},[3655],{"nctId":803,"briefTitle":804,"status":503,"phases":3656,"primaryCompletion":806,"completion":806,"start":807,"enrollment":98,"conditions":3657,"interventions":3658},[88,89],[809],[811,812,794],{"trials":3660,"activeCount":98},[],{"trials":3662,"activeCount":98},[],{"trials":3664,"activeCount":98},[],{"intervention":3666,"totalTrials":228,"cells":3667},"activase",{"EARLY_PHASE1":3668,"PHASE1":3670,"PHASE2":3672,"PHASE3":3683,"PHASE4":3685,"NA":3687},{"trials":3669,"activeCount":98},[],{"trials":3671,"activeCount":98},[],{"trials":3673,"activeCount":98},[3674],{"nctId":3675,"briefTitle":3676,"status":136,"phases":3677,"completion":3678,"start":3679,"enrollment":1330,"conditions":3680,"interventions":3681},"NCT00250991","Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke (CLEAR Stroke) Trial",[88,89],"2007-07","2003-07",[15],[3666,3682],"integrilin",{"trials":3684,"activeCount":98},[],{"trials":3686,"activeCount":98},[],{"trials":3688,"activeCount":98},[],{"intervention":3682,"totalTrials":228,"cells":3690},{"EARLY_PHASE1":3691,"PHASE1":3693,"PHASE2":3695,"PHASE3":3701,"PHASE4":3703,"NA":3705},{"trials":3692,"activeCount":98},[],{"trials":3694,"activeCount":98},[],{"trials":3696,"activeCount":98},[3697],{"nctId":3675,"briefTitle":3676,"status":136,"phases":3698,"completion":3678,"start":3679,"enrollment":1330,"conditions":3699,"interventions":3700},[88,89],[15],[3666,3682],{"trials":3702,"activeCount":98},[],{"trials":3704,"activeCount":98},[],{"trials":3706,"activeCount":98},[],{"intervention":3708,"totalTrials":228,"cells":3709},"Liposomal bupivacaine",{"EARLY_PHASE1":3710,"PHASE1":3712,"PHASE2":3714,"PHASE3":3728,"PHASE4":3730,"NA":3732},{"trials":3711,"activeCount":98},[],{"trials":3713,"activeCount":98},[],{"trials":3715,"activeCount":98},[3716],{"nctId":3717,"briefTitle":3718,"status":136,"phases":3719,"primaryCompletion":3720,"completion":3720,"start":3721,"enrollment":213,"conditions":3722,"interventions":3726},"NCT02749968","Intercostal Liposomal Bupivacaine for the Management of Blunt Chest Wall Trauma",[89],"2021-01-01","2018-03-09",[3723,3724,3725],"Blunt Chest Wall Trauma","Rib Fracture","Sternal Fracture",[3708,3727],"0.9% sodium chloride",{"trials":3729,"activeCount":98},[],{"trials":3731,"activeCount":98},[],{"trials":3733,"activeCount":98},[],{"intervention":3727,"totalTrials":228,"cells":3735},{"EARLY_PHASE1":3736,"PHASE1":3738,"PHASE2":3740,"PHASE3":3746,"PHASE4":3748,"NA":3750},{"trials":3737,"activeCount":98},[],{"trials":3739,"activeCount":98},[],{"trials":3741,"activeCount":98},[3742],{"nctId":3717,"briefTitle":3718,"status":136,"phases":3743,"primaryCompletion":3720,"completion":3720,"start":3721,"enrollment":213,"conditions":3744,"interventions":3745},[89],[3723,3724,3725],[3708,3727],{"trials":3747,"activeCount":98},[],{"trials":3749,"activeCount":98},[],{"trials":3751,"activeCount":98},[],{"intervention":3753,"totalTrials":228,"cells":3754},"betahistine dihydrochloride",{"EARLY_PHASE1":3755,"PHASE1":3757,"PHASE2":3759,"PHASE3":3769,"PHASE4":3771,"NA":3773},{"trials":3756,"activeCount":98},[],{"trials":3758,"activeCount":98},[],{"trials":3760,"activeCount":98},[3761],{"nctId":3762,"briefTitle":3763,"status":756,"phases":3764,"primaryCompletion":3765,"completion":3765,"start":3678,"enrollment":228,"conditions":3766,"interventions":3768},"NCT00585585","Pilot Study of Betahistine Dihydrochloride in the Treatment of Major Depression With Atypical Features",[89],"2011-01",[3767],"Recurrent Major Depressive Disorder With Atypical Features",[3753],{"trials":3770,"activeCount":98},[],{"trials":3772,"activeCount":98},[],{"trials":3774,"activeCount":98},[],{"intervention":3776,"totalTrials":228,"cells":3777},"Axitinib",{"EARLY_PHASE1":3778,"PHASE1":3780,"PHASE2":3782,"PHASE3":3790,"PHASE4":3792,"NA":3794},{"trials":3779,"activeCount":98},[],{"trials":3781,"activeCount":98},[],{"trials":3783,"activeCount":98},[3784],{"nctId":3785,"briefTitle":3786,"status":756,"phases":3787,"primaryCompletion":2956,"completion":2956,"start":2722,"enrollment":228,"conditions":3788,"interventions":3789},"NCT01508117","Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients",[89],[809],[3776],{"trials":3791,"activeCount":98},[],{"trials":3793,"activeCount":98},[],{"trials":3795,"activeCount":98},[],{"intervention":3797,"totalTrials":228,"cells":3798},"Recombinant tissue plasminogen activator",{"EARLY_PHASE1":3799,"PHASE1":3801,"PHASE2":3803,"PHASE3":3814,"PHASE4":3816,"NA":3818},{"trials":3800,"activeCount":98},[],{"trials":3802,"activeCount":98},[],{"trials":3804,"activeCount":98},[3805],{"nctId":3806,"briefTitle":3807,"status":136,"phases":3808,"primaryCompletion":3809,"completion":1491,"start":3810,"enrollment":3811,"conditions":3812,"interventions":3813},"NCT00243906","Interventional Management of Stroke (IMS) II Study",[89],"2006-05","2003-01",81,[15],[3797],{"trials":3815,"activeCount":98},[],{"trials":3817,"activeCount":98},[],{"trials":3819,"activeCount":98},[],{"intervention":3821,"totalTrials":228,"cells":3822},"Eltrombopag",{"EARLY_PHASE1":3823,"PHASE1":3825,"PHASE2":3827,"PHASE3":3836,"PHASE4":3838,"NA":3840},{"trials":3824,"activeCount":98},[],{"trials":3826,"activeCount":98},[],{"trials":3828,"activeCount":98},[3829],{"nctId":3830,"briefTitle":3831,"status":503,"phases":3832,"primaryCompletion":760,"completion":760,"start":506,"enrollment":98,"conditions":3833,"interventions":3835},"NCT01194167","Study of Eltrombopag in Platelet Refractory Thrombocytopenia",[89],[3834],"Thrombocytopenia",[3821],{"trials":3837,"activeCount":98},[],{"trials":3839,"activeCount":98},[],{"trials":3841,"activeCount":98},[],{"intervention":511,"totalTrials":228,"cells":3843},{"EARLY_PHASE1":3844,"PHASE1":3846,"PHASE2":3848,"PHASE3":3854,"PHASE4":3856,"NA":3858},{"trials":3845,"activeCount":98},[],{"trials":3847,"activeCount":98},[],{"trials":3849,"activeCount":98},[3850],{"nctId":501,"briefTitle":502,"status":503,"phases":3851,"primaryCompletion":505,"completion":506,"start":507,"enrollment":98,"conditions":3852,"interventions":3853},[89],[509],[479,511,512],{"trials":3855,"activeCount":98},[],{"trials":3857,"activeCount":98},[],{"trials":3859,"activeCount":98},[],{"intervention":3861,"totalTrials":228,"cells":3862},"Nicardipine",{"EARLY_PHASE1":3863,"PHASE1":3865,"PHASE2":3867,"PHASE3":3882,"PHASE4":3884,"NA":3886},{"trials":3864,"activeCount":98},[],{"trials":3866,"activeCount":98},[],{"trials":3868,"activeCount":98},[3869],{"nctId":3870,"briefTitle":3871,"status":136,"phases":3872,"primaryCompletion":3873,"completion":3874,"start":3875,"enrollment":780,"conditions":3876,"interventions":3879},"NCT04116112","Blood Pressure After Endovascular Stroke Therapy-II",[89],"2022-07-01","2022-12-15","2020-01-17",[3877,3878],"Acute Stroke","Endovascular Thrombectomy",[3861,3880,3881],"Labetalol","Hydralazine",{"trials":3883,"activeCount":98},[],{"trials":3885,"activeCount":98},[],{"trials":3887,"activeCount":98},[],{"intervention":3880,"totalTrials":228,"cells":3889},{"EARLY_PHASE1":3890,"PHASE1":3892,"PHASE2":3894,"PHASE3":3900,"PHASE4":3902,"NA":3904},{"trials":3891,"activeCount":98},[],{"trials":3893,"activeCount":98},[],{"trials":3895,"activeCount":98},[3896],{"nctId":3870,"briefTitle":3871,"status":136,"phases":3897,"primaryCompletion":3873,"completion":3874,"start":3875,"enrollment":780,"conditions":3898,"interventions":3899},[89],[3877,3878],[3861,3880,3881],{"trials":3901,"activeCount":98},[],{"trials":3903,"activeCount":98},[],{"trials":3905,"activeCount":98},[],{"intervention":3881,"totalTrials":228,"cells":3907},{"EARLY_PHASE1":3908,"PHASE1":3910,"PHASE2":3912,"PHASE3":3918,"PHASE4":3920,"NA":3922},{"trials":3909,"activeCount":98},[],{"trials":3911,"activeCount":98},[],{"trials":3913,"activeCount":98},[3914],{"nctId":3870,"briefTitle":3871,"status":136,"phases":3915,"primaryCompletion":3873,"completion":3874,"start":3875,"enrollment":780,"conditions":3916,"interventions":3917},[89],[3877,3878],[3861,3880,3881],{"trials":3919,"activeCount":98},[],{"trials":3921,"activeCount":98},[],{"trials":3923,"activeCount":98},[],{"intervention":496,"totalTrials":228,"cells":3925},{"EARLY_PHASE1":3926,"PHASE1":3928,"PHASE2":3934,"PHASE3":3936,"PHASE4":3938,"NA":3940},{"trials":3927,"activeCount":98},[],{"trials":3929,"activeCount":98},[3930],{"nctId":486,"briefTitle":487,"status":136,"phases":3931,"primaryCompletion":489,"completion":490,"start":491,"enrollment":393,"conditions":3932,"interventions":3933},[88],[493,494],[496,497,479],{"trials":3935,"activeCount":98},[],{"trials":3937,"activeCount":98},[],{"trials":3939,"activeCount":98},[],{"trials":3941,"activeCount":98},[],{"intervention":497,"totalTrials":228,"cells":3943},{"EARLY_PHASE1":3944,"PHASE1":3946,"PHASE2":3952,"PHASE3":3954,"PHASE4":3956,"NA":3958},{"trials":3945,"activeCount":98},[],{"trials":3947,"activeCount":98},[3948],{"nctId":486,"briefTitle":487,"status":136,"phases":3949,"primaryCompletion":489,"completion":490,"start":491,"enrollment":393,"conditions":3950,"interventions":3951},[88],[493,494],[496,497,479],{"trials":3953,"activeCount":98},[],{"trials":3955,"activeCount":98},[],{"trials":3957,"activeCount":98},[],{"trials":3959,"activeCount":98},[],{"intervention":3961,"totalTrials":228,"cells":3962},"Docetaxel",{"EARLY_PHASE1":3963,"PHASE1":3965,"PHASE2":3974,"PHASE3":3976,"PHASE4":3978,"NA":3980},{"trials":3964,"activeCount":98},[],{"trials":3966,"activeCount":98},[3967],{"nctId":3968,"briefTitle":3969,"status":756,"phases":3970,"primaryCompletion":3971,"completion":3971,"start":1172,"enrollment":28,"conditions":3972,"interventions":3973},"NCT02110992","Safety Study of SBRT and Docetaxel for Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Head and Neck",[88],"2017-03-29",[461],[3961],{"trials":3975,"activeCount":98},[],{"trials":3977,"activeCount":98},[],{"trials":3979,"activeCount":98},[],{"trials":3981,"activeCount":98},[],{"intervention":3983,"totalTrials":228,"cells":3984},"OROS-MPH",{"EARLY_PHASE1":3985,"PHASE1":3987,"PHASE2":3999,"PHASE3":4001,"PHASE4":4003,"NA":4005},{"trials":3986,"activeCount":98},[],{"trials":3988,"activeCount":98},[3989],{"nctId":3990,"briefTitle":3991,"status":136,"phases":3992,"primaryCompletion":3993,"completion":3993,"start":928,"enrollment":3994,"conditions":3995,"interventions":3998},"NCT00603434","Safety Assessment of Potential Interactions Between IV Methamphetamine and Osmotic-Release Methylphenidate (OROS-MPH)",[88],"2009-03",16,[3996,3997],"Methamphetamine Dependence","Methamphetamine Abuse",[3983,3983,3983],{"trials":4000,"activeCount":98},[],{"trials":4002,"activeCount":98},[],{"trials":4004,"activeCount":98},[],{"trials":4006,"activeCount":98},[],{"intervention":4008,"totalTrials":228,"cells":4009},"Metformin",{"EARLY_PHASE1":4010,"PHASE1":4012,"PHASE2":4024,"PHASE3":4026,"PHASE4":4028,"NA":4030},{"trials":4011,"activeCount":98},[],{"trials":4013,"activeCount":98},[4014],{"nctId":4015,"briefTitle":4016,"status":136,"phases":4017,"primaryCompletion":4018,"completion":4019,"start":4020,"enrollment":328,"conditions":4021,"interventions":4022},"NCT02325401","Dose-finding Study of Metformin With Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma",[88],"2017-12-26","2020-02-21","2015-05-11",[461],[4008,4023],"Cisplatin",{"trials":4025,"activeCount":98},[],{"trials":4027,"activeCount":98},[],{"trials":4029,"activeCount":98},[],{"trials":4031,"activeCount":98},[],{"intervention":4023,"totalTrials":228,"cells":4033},{"EARLY_PHASE1":4034,"PHASE1":4036,"PHASE2":4042,"PHASE3":4044,"PHASE4":4046,"NA":4048},{"trials":4035,"activeCount":98},[],{"trials":4037,"activeCount":98},[4038],{"nctId":4015,"briefTitle":4016,"status":136,"phases":4039,"primaryCompletion":4018,"completion":4019,"start":4020,"enrollment":328,"conditions":4040,"interventions":4041},[88],[461],[4008,4023],{"trials":4043,"activeCount":98},[],{"trials":4045,"activeCount":98},[],{"trials":4047,"activeCount":98},[],{"trials":4049,"activeCount":98},[],{"intervention":4051,"totalTrials":228,"cells":4052},"Efavirenz",{"EARLY_PHASE1":4053,"PHASE1":4055,"PHASE2":4066,"PHASE3":4068,"PHASE4":4070,"NA":4072},{"trials":4054,"activeCount":98},[],{"trials":4056,"activeCount":98},[4057],{"nctId":4058,"briefTitle":4059,"status":136,"phases":4060,"primaryCompletion":4061,"completion":4061,"start":1163,"enrollment":16,"conditions":4062,"interventions":4064},"NCT00545558","Effects of Anti-HIV Drugs on the Hepatitis C Virus (HCV) in Adults Infected With Both HCV and HIV",[88],"2012-03",[4063,2144],"Hepatitis C",[4051,4065],"Emtricitabine\u002FTenofovir disoproxil fumarate",{"trials":4067,"activeCount":98},[],{"trials":4069,"activeCount":98},[],{"trials":4071,"activeCount":98},[],{"trials":4073,"activeCount":98},[],{"intervention":4065,"totalTrials":228,"cells":4075},{"EARLY_PHASE1":4076,"PHASE1":4078,"PHASE2":4084,"PHASE3":4086,"PHASE4":4088,"NA":4090},{"trials":4077,"activeCount":98},[],{"trials":4079,"activeCount":98},[4080],{"nctId":4058,"briefTitle":4059,"status":136,"phases":4081,"primaryCompletion":4061,"completion":4061,"start":1163,"enrollment":16,"conditions":4082,"interventions":4083},[88],[4063,2144],[4051,4065],{"trials":4085,"activeCount":98},[],{"trials":4087,"activeCount":98},[],{"trials":4089,"activeCount":98},[],{"trials":4091,"activeCount":98},[],{"intervention":765,"totalTrials":228,"cells":4093},{"EARLY_PHASE1":4094,"PHASE1":4096,"PHASE2":4102,"PHASE3":4104,"PHASE4":4106,"NA":4108},{"trials":4095,"activeCount":98},[],{"trials":4097,"activeCount":98},[4098],{"nctId":754,"briefTitle":755,"status":756,"phases":4099,"primaryCompletion":758,"completion":759,"start":760,"enrollment":761,"conditions":4100,"interventions":4101},[88],[763],[765,352],{"trials":4103,"activeCount":98},[],{"trials":4105,"activeCount":98},[],{"trials":4107,"activeCount":98},[],{"trials":4109,"activeCount":98},[],{"intervention":1334,"totalTrials":228,"cells":4111},{"EARLY_PHASE1":4112,"PHASE1":4118,"PHASE2":4120,"PHASE3":4122,"PHASE4":4124,"NA":4126},{"trials":4113,"activeCount":98},[4114],{"nctId":1324,"briefTitle":1325,"status":136,"phases":4115,"primaryCompletion":1327,"completion":1328,"start":1329,"enrollment":1330,"conditions":4116,"interventions":4117},[87],[1332],[1334,1319],{"trials":4119,"activeCount":98},[],{"trials":4121,"activeCount":98},[],{"trials":4123,"activeCount":98},[],{"trials":4125,"activeCount":98},[],{"trials":4127,"activeCount":98},[],{"intervention":4129,"totalTrials":228,"cells":4130},"Gadoxetate Sodium",{"EARLY_PHASE1":4131,"PHASE1":4144,"PHASE2":4146,"PHASE3":4148,"PHASE4":4150,"NA":4152},{"trials":4132,"activeCount":98},[4133],{"nctId":4134,"briefTitle":4135,"status":775,"phases":4136,"primaryCompletion":4137,"completion":4138,"start":4139,"enrollment":468,"conditions":4140,"interventions":4143},"NCT03960788","Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer",[87],"2020-01-02","2021-01-02","2018-01-02",[4141,4142],"Cancer of the Prostate","Castration-resistant Prostate Cancer",[4129],{"trials":4145,"activeCount":98},[],{"trials":4147,"activeCount":98},[],{"trials":4149,"activeCount":98},[],{"trials":4151,"activeCount":98},[],{"trials":4153,"activeCount":98},[],{"intervention":1616,"totalTrials":34,"cells":4155},{"EARLY_PHASE1":4156,"PHASE1":4158,"PHASE2":4160,"PHASE3":4162,"PHASE4":4180,"NA":4193},{"trials":4157,"activeCount":98},[],{"trials":4159,"activeCount":98},[],{"trials":4161,"activeCount":98},[],{"trials":4163,"activeCount":98},[4164,4171],{"nctId":4165,"briefTitle":4166,"status":136,"phases":4167,"primaryCompletion":326,"completion":326,"start":2142,"enrollment":627,"conditions":4168,"interventions":4170},"NCT00232414","A Double-Blind Randomized Placebo Controlled Study of Quetiapine for the Treatment of Depression in Adolescents With Bipolar Disorder",[90],[4169],"Bipolar I Disorder",[1616],{"nctId":4172,"briefTitle":4173,"status":136,"phases":4174,"primaryCompletion":1163,"completion":1163,"start":4175,"enrollment":328,"conditions":4176,"interventions":4178},"NCT00221468","A Study of Quetiapine for the Treatment of Mood Disorders in Adolescents",[90],"2003-06",[4177],"Mood Disorders",[4179],"quetiapine",{"trials":4181,"activeCount":98},[4182,4186],{"nctId":1607,"briefTitle":1608,"status":503,"phases":4183,"completion":1610,"start":181,"enrollment":98,"conditions":4184,"interventions":4185},[91],[1612,1613,1614],[1594,1616],{"nctId":4187,"briefTitle":4188,"status":136,"phases":4189,"primaryCompletion":912,"completion":912,"start":1008,"enrollment":328,"conditions":4190,"interventions":4192},"NCT01200901","Quetiapine in Melancholic Depression",[91],[27,4191],"Healthy",[1616],{"trials":4194,"activeCount":98},[4195],{"nctId":4196,"briefTitle":4197,"status":136,"phases":4198,"primaryCompletion":3362,"completion":1396,"start":928,"enrollment":3811,"conditions":4199,"interventions":4200},"NCT00609193","Functional and Neurochemical Brain Changes in First-episode Bipolar Mania",[],[21],[4201,4179],"lithium",{"intervention":4201,"totalTrials":194,"cells":4203},{"EARLY_PHASE1":4204,"PHASE1":4206,"PHASE2":4208,"PHASE3":4210,"PHASE4":4212,"NA":4223},{"trials":4205,"activeCount":98},[],{"trials":4207,"activeCount":98},[],{"trials":4209,"activeCount":98},[],{"trials":4211,"activeCount":98},[],{"trials":4213,"activeCount":98},[4214],{"nctId":4215,"briefTitle":4216,"status":775,"phases":4217,"primaryCompletion":1396,"completion":3338,"start":4218,"enrollment":4219,"conditions":4220,"interventions":4221},"NCT00608075","Neurofunctional and Neurochemical Markers of Treatment Response in Bipolar Disorder",[91],"2007-04",260,[4169],[4201,4222],"Lithium",{"trials":4224,"activeCount":98},[4225],{"nctId":4196,"briefTitle":4197,"status":136,"phases":4226,"primaryCompletion":3362,"completion":1396,"start":928,"enrollment":3811,"conditions":4227,"interventions":4228},[],[21],[4201,4179],{"intervention":1015,"totalTrials":194,"cells":4230},{"EARLY_PHASE1":4231,"PHASE1":4233,"PHASE2":4235,"PHASE3":4241,"PHASE4":4243,"NA":4245},{"trials":4232,"activeCount":98},[],{"trials":4234,"activeCount":98},[],{"trials":4236,"activeCount":98},[4237],{"nctId":1003,"briefTitle":1004,"status":136,"phases":4238,"primaryCompletion":1006,"completion":1007,"start":1008,"enrollment":627,"conditions":4239,"interventions":4240},[89],[1010],[994,1012,1013,1014,1015,1016],{"trials":4242,"activeCount":98},[],{"trials":4244,"activeCount":98},[],{"trials":4246,"activeCount":98},[4247],{"nctId":4248,"briefTitle":4249,"status":775,"phases":4250,"primaryCompletion":4251,"completion":4251,"start":4252,"enrollment":213,"conditions":4253,"interventions":4257},"NCT04612803","Prevalence of Antihistamine Responsive Irritable Bowel Syndrome With Diarrhea",[],"2021-08-01","2020-11-15",[4254,4255,4256],"Irritable Bowel Syndrome","Dermatographism","Post-prandial Diarrhea",[1015],{"intervention":4259,"totalTrials":228,"cells":4260},"IVF Antagonist Protocol",{"EARLY_PHASE1":4261,"PHASE1":4263,"PHASE2":4265,"PHASE3":4267,"PHASE4":4269,"NA":4271},{"trials":4262,"activeCount":98},[],{"trials":4264,"activeCount":98},[],{"trials":4266,"activeCount":98},[],{"trials":4268,"activeCount":98},[],{"trials":4270,"activeCount":98},[],{"trials":4272,"activeCount":98},[4273],{"nctId":4274,"briefTitle":4275,"status":775,"phases":4276,"primaryCompletion":4277,"completion":4278,"start":1287,"enrollment":627,"conditions":4279,"interventions":4282},"NCT01487486","Proteomics & Glyco-Proteomic Analysis of Follicular Fluid",[],"2013-12","2014-01",[4280,4281],"Polycystic Ovary Syndrome","Normal Volunteers",[4259],{"intervention":4284,"totalTrials":228,"cells":4285},"chenodeoxycholic acid",{"EARLY_PHASE1":4286,"PHASE1":4288,"PHASE2":4290,"PHASE3":4292,"PHASE4":4294,"NA":4296},{"trials":4287,"activeCount":98},[],{"trials":4289,"activeCount":98},[],{"trials":4291,"activeCount":98},[],{"trials":4293,"activeCount":98},[],{"trials":4295,"activeCount":98},[],{"trials":4297,"activeCount":98},[4298],{"nctId":4299,"briefTitle":4300,"status":756,"phases":4301,"completion":2485,"enrollment":11,"conditions":4302,"interventions":4307},"NCT00004442","Study of Bile Acids in Patients With Peroxisomal Disorders",[92],[4303,4304,4305,4306],"Infantile Refsum's Disease","Zellweger Syndrome","Bifunctional Enzyme Deficiency","Adrenoleukodystrophy",[4284,4308,4309],"cholic acid","ursodiol",{"intervention":4308,"totalTrials":228,"cells":4311},{"EARLY_PHASE1":4312,"PHASE1":4314,"PHASE2":4316,"PHASE3":4318,"PHASE4":4320,"NA":4322},{"trials":4313,"activeCount":98},[],{"trials":4315,"activeCount":98},[],{"trials":4317,"activeCount":98},[],{"trials":4319,"activeCount":98},[],{"trials":4321,"activeCount":98},[],{"trials":4323,"activeCount":98},[4324],{"nctId":4299,"briefTitle":4300,"status":756,"phases":4325,"completion":2485,"enrollment":11,"conditions":4326,"interventions":4327},[92],[4303,4304,4305,4306],[4284,4308,4309],{"intervention":4309,"totalTrials":228,"cells":4329},{"EARLY_PHASE1":4330,"PHASE1":4332,"PHASE2":4334,"PHASE3":4336,"PHASE4":4338,"NA":4340},{"trials":4331,"activeCount":98},[],{"trials":4333,"activeCount":98},[],{"trials":4335,"activeCount":98},[],{"trials":4337,"activeCount":98},[],{"trials":4339,"activeCount":98},[],{"trials":4341,"activeCount":98},[4342],{"nctId":4299,"briefTitle":4300,"status":756,"phases":4343,"completion":2485,"enrollment":11,"conditions":4344,"interventions":4345},[92],[4303,4304,4305,4306],[4284,4308,4309],{"intervention":4347,"totalTrials":228,"cells":4348},"Loop diuretics",{"EARLY_PHASE1":4349,"PHASE1":4351,"PHASE2":4353,"PHASE3":4355,"PHASE4":4357,"NA":4359},{"trials":4350,"activeCount":98},[],{"trials":4352,"activeCount":98},[],{"trials":4354,"activeCount":98},[],{"trials":4356,"activeCount":98},[],{"trials":4358,"activeCount":98},[],{"trials":4360,"activeCount":98},[4361],{"nctId":4362,"briefTitle":4363,"status":756,"phases":4364,"primaryCompletion":4365,"completion":4365,"start":4366,"enrollment":154,"conditions":4367,"interventions":4369},"NCT01457053","Assessment of Coronary Flow Reserve in Heart Failure Patients After Ultrafiltration Versus Diuretics",[92],"2013-05","2011-11",[4368],"Acute Decompensated Heart Failure",[4347],{"intervention":4371,"totalTrials":228,"cells":4372},"N-acetyl cysteine",{"EARLY_PHASE1":4373,"PHASE1":4375,"PHASE2":4377,"PHASE3":4379,"PHASE4":4381,"NA":4383},{"trials":4374,"activeCount":98},[],{"trials":4376,"activeCount":98},[],{"trials":4378,"activeCount":98},[],{"trials":4380,"activeCount":98},[],{"trials":4382,"activeCount":98},[],{"trials":4384,"activeCount":98},[4385],{"nctId":4386,"briefTitle":4387,"status":775,"phases":4388,"primaryCompletion":4389,"completion":4390,"start":1196,"enrollment":4391,"conditions":4392,"interventions":4393},"NCT02865629","N-acetylcysteine in the Treatment of Depressive Symptoms in Bipolar Offspring",[92],"2019-08","2019-09",22,[27],[4371],{"intervention":4395,"totalTrials":228,"cells":4396},"4% Topical Lidocaine Gel",{"EARLY_PHASE1":4397,"PHASE1":4399,"PHASE2":4401,"PHASE3":4403,"PHASE4":4405,"NA":4407},{"trials":4398,"activeCount":98},[],{"trials":4400,"activeCount":98},[],{"trials":4402,"activeCount":98},[],{"trials":4404,"activeCount":98},[],{"trials":4406,"activeCount":98},[],{"trials":4408,"activeCount":98},[4409],{"nctId":4410,"briefTitle":4411,"status":775,"phases":4412,"primaryCompletion":4413,"completion":4414,"start":4415,"enrollment":4416,"conditions":4417,"interventions":4418},"NCT03257670","Fractional CO2 Laser Therapy Versus 4% Topical Lidocaine Gel for Dyspareunia in Breast Cancer Survivors",[92],"2022-01-01","2022-06-01","2018-03-20",70,[2445],[4395],{"intervention":4420,"totalTrials":228,"cells":4421},"naloxone nasal spray kit",{"EARLY_PHASE1":4422,"PHASE1":4424,"PHASE2":4426,"PHASE3":4428,"PHASE4":4430,"NA":4432},{"trials":4423,"activeCount":98},[],{"trials":4425,"activeCount":98},[],{"trials":4427,"activeCount":98},[],{"trials":4429,"activeCount":98},[],{"trials":4431,"activeCount":98},[],{"trials":4433,"activeCount":98},[4434],{"nctId":4435,"briefTitle":4436,"status":136,"phases":4437,"primaryCompletion":4438,"completion":4438,"start":4439,"enrollment":4440,"conditions":4441,"interventions":4446},"NCT02922959","A Tailored, Peer-delivered Intervention to Reduce Recurring Opioid Overdoses",[92],"2019-07-25","2017-02-07",80,[4442,4443,4444,4445,968],"Drug Overdose","Opioid-Related Disorders","Drug Addiction","Drug Abuse",[4420],{"intervention":4448,"totalTrials":228,"cells":4449},"Quetiapine & Placebo",{"EARLY_PHASE1":4450,"PHASE1":4452,"PHASE2":4454,"PHASE3":4456,"PHASE4":4458,"NA":4460},{"trials":4451,"activeCount":98},[],{"trials":4453,"activeCount":98},[],{"trials":4455,"activeCount":98},[],{"trials":4457,"activeCount":98},[],{"trials":4459,"activeCount":98},[],{"trials":4461,"activeCount":98},[4462],{"nctId":4463,"briefTitle":4464,"status":136,"phases":4465,"primaryCompletion":4466,"completion":2245,"start":3993,"enrollment":4467,"conditions":4468,"interventions":4469},"NCT00893581","Multimodal Neuroimaging of Treatment Effects in Adolescent Mania",[92],"2016-02",169,[3535,21],[4448,4470],"Lithium and Placebo",{"intervention":4470,"totalTrials":228,"cells":4472},{"EARLY_PHASE1":4473,"PHASE1":4475,"PHASE2":4477,"PHASE3":4479,"PHASE4":4481,"NA":4483},{"trials":4474,"activeCount":98},[],{"trials":4476,"activeCount":98},[],{"trials":4478,"activeCount":98},[],{"trials":4480,"activeCount":98},[],{"trials":4482,"activeCount":98},[],{"trials":4484,"activeCount":98},[4485],{"nctId":4463,"briefTitle":4464,"status":136,"phases":4486,"primaryCompletion":4466,"completion":2245,"start":3993,"enrollment":4467,"conditions":4487,"interventions":4488},[92],[3535,21],[4448,4470],{"intervention":4490,"totalTrials":228,"cells":4491},"Misoprostol",{"EARLY_PHASE1":4492,"PHASE1":4494,"PHASE2":4496,"PHASE3":4498,"PHASE4":4500,"NA":4502},{"trials":4493,"activeCount":98},[],{"trials":4495,"activeCount":98},[],{"trials":4497,"activeCount":98},[],{"trials":4499,"activeCount":98},[],{"trials":4501,"activeCount":98},[],{"trials":4503,"activeCount":98},[4504],{"nctId":4505,"briefTitle":4506,"status":775,"phases":4507,"primaryCompletion":4508,"completion":4509,"start":4510,"enrollment":4511,"conditions":4512,"interventions":4514},"NCT03748147","Cervical Ripening in Obese Women: Efficacy of 25 mcg Versus 50 mcg of Misoprostol",[92],"2020-06-01","2021-03-01","2018-12-10",300,[4513],"Induction of Labor Affected Fetus \u002F Newborn",[4490],{"intervention":4516,"totalTrials":228,"cells":4517},"cephalexin & metronidazole",{"EARLY_PHASE1":4518,"PHASE1":4520,"PHASE2":4522,"PHASE3":4524,"PHASE4":4526,"NA":4528},{"trials":4519,"activeCount":98},[],{"trials":4521,"activeCount":98},[],{"trials":4523,"activeCount":98},[],{"trials":4525,"activeCount":98},[],{"trials":4527,"activeCount":98},[],{"trials":4529,"activeCount":98},[4530],{"nctId":4531,"briefTitle":4532,"status":775,"phases":4533,"primaryCompletion":912,"start":314,"enrollment":4534,"conditions":4535,"interventions":4537},"NCT01194115","Use of 48 Hour Course of Antibiotics to Prevent Surgical Site Infection in Obese Patients Undergoing Cesarean Delivery",[92],475,[4536],"Surgical Site Infection in Obese Women Undergoing C-section",[4516],{"intervention":4539,"totalTrials":228,"cells":4540},"Magnesium sulfate",{"EARLY_PHASE1":4541,"PHASE1":4543,"PHASE2":4545,"PHASE3":4547,"PHASE4":4549,"NA":4551},{"trials":4542,"activeCount":98},[],{"trials":4544,"activeCount":98},[],{"trials":4546,"activeCount":98},[],{"trials":4548,"activeCount":98},[],{"trials":4550,"activeCount":98},[],{"trials":4552,"activeCount":98},[4553],{"nctId":4554,"briefTitle":4555,"status":756,"phases":4556,"primaryCompletion":180,"completion":180,"start":4557,"enrollment":419,"conditions":4558,"interventions":4561},"NCT00306462","Trial of Magnesium Sulfate Tocolysis Versus Nifedipine Tocolysis in Women With Preterm Labor",[92],"2006-03",[4559,4560],"Premature Birth","Premature Labor",[4539,4562],"Oral Nifedipine or placebo",{"intervention":4562,"totalTrials":228,"cells":4564},{"EARLY_PHASE1":4565,"PHASE1":4567,"PHASE2":4569,"PHASE3":4571,"PHASE4":4573,"NA":4575},{"trials":4566,"activeCount":98},[],{"trials":4568,"activeCount":98},[],{"trials":4570,"activeCount":98},[],{"trials":4572,"activeCount":98},[],{"trials":4574,"activeCount":98},[],{"trials":4576,"activeCount":98},[4577],{"nctId":4554,"briefTitle":4555,"status":756,"phases":4578,"primaryCompletion":180,"completion":180,"start":4557,"enrollment":419,"conditions":4579,"interventions":4580},[92],[4559,4560],[4539,4562],{"intervention":4582,"totalTrials":228,"cells":4583},"Citalopram",{"EARLY_PHASE1":4584,"PHASE1":4586,"PHASE2":4588,"PHASE3":4590,"PHASE4":4592,"NA":4594},{"trials":4585,"activeCount":98},[],{"trials":4587,"activeCount":98},[],{"trials":4589,"activeCount":98},[],{"trials":4591,"activeCount":98},[],{"trials":4593,"activeCount":98},[],{"trials":4595,"activeCount":98},[4596],{"nctId":4597,"briefTitle":4598,"status":136,"phases":4599,"primaryCompletion":2722,"completion":3161,"start":951,"enrollment":4600,"conditions":4601,"interventions":4604},"NCT00226694","Alcohol and Gender Effects on Stress Circuit Function",[92],96,[3275,4602,4603],"Stress","Alcohol Dependence",[4582]]